



## CURRICULUM VITAE

### **Daniel K. Nomura, Ph.D.**

Professor of Chemical Biology and Molecular Therapeutics  
University of California, Berkeley  
Departments of Chemistry and Molecular and Cell Biology  
Innovative Genomics Institute  
2151 Berkeley Way, Rm 312G  
Berkeley, CA 94720  
DNomura@berkeley.edu  
Office: 510-643-7258  
Cell: 510-798-9647  
Nomuraresearchgroup.com

---

#### **Education**

- 2008-2011 Postdoctoral Fellow in Chemical Physiology  
Scripps Research (Advisor: Benjamin F. Cravatt)
- 2004-2008 Ph.D. in Molecular Toxicology  
University of California, Berkeley (Advisor: John E. Casida)
- 1999-2003 B.A. in Molecular and Cell Biology  
University of California, Berkeley (Advisor: John E. Casida)

#### **Positions**

- 2024-current Co-Director, Molecular Therapeutics Initiative, UC Berkeley
- 2023-current Professor (with tenure)  
University of California, Berkeley  
Department of Chemistry (50 % primary)  
Department of Molecular and Cell Biology, Division of Molecular Therapeutics (50 %)  
Department of Nutritional Sciences and Toxicology (0%)
- 2019-2023 Professor (with tenure)  
University of California, Berkeley  
Departments of Chemistry (50%), Nutritional Sciences and Toxicology (50%), and  
Molecular and Cell Biology (0%)
- 2019-current Adjunct Professor  
University of California, San Francisco; Department of Pharmaceutical Chemistry
- 2017-current Director, Novartis-Berkeley Translational Chemical Biology Institute (NB-TCBI)
- 2016-2019 Associate Adjunct Professor  
University of California, San Francisco  
Department of Pharmaceutical Chemistry
- 2015-2019 Associate Professor (with tenure)  
University of California, Berkeley  
Departments of Nutritional Sciences and Toxicology (100%), Chemistry (0%),  
and Molecular and Cell Biology (0%)
- 2011-2015 Assistant Professor  
University of California, Berkeley  
Department of Nutritional Sciences and Toxicology
- 2008-2011 Postdoctoral Fellow  
Scripps Research, La Jolla, CA; Department of Chemical Physiology  
Advisor: Professor Benjamin F. Cravatt
- 2004-2008 Graduate Researcher
- 2003-2004 Research Associate
- 2000-2003 Undergraduate Research Assistant  
University of California, Berkeley  
Department of Nutritional Sciences and Toxicology  
Advisor: Professor John E. Casida

## Daniel K. Nomura Biography

Dan Nomura is a Professor of Chemical Biology and Molecular Therapeutics in the Department of Chemistry and the Department of Molecular and Cell Biology in the Division of Molecular Therapeutics at the University of California, Berkeley and an Investigator at the Innovative Genomics Institute. He is also the Co-Director of the Molecular Therapeutics Initiative at UC Berkeley. He is an Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF. Since 2017, he has been the Director of the Novartis-Berkeley Translational Chemical Biology Institute focused on using chemoproteomic platforms to tackle the undruggable proteome. He is Co-Founder of Frontier Medicines, a start-up company focused on using chemoproteomics and machine learning approaches to tackle the undruggable proteome. He is also the Founder of Vicinitas Therapeutics based on his group's discovery of the Deubiquitinase Targeting Chimera (DUBTAC) platform for targeted protein stabilization. He is on the Scientific Advisory Boards for Frontier Medicines, Vicinitas Therapeutics, Photys Therapeutics, Apertor Pharma, Ecto Therapeutics, Oerth Bio, and Deciphera Pharmaceuticals. Nomura is also on the scientific advisory boards of The Mark Foundation for Cancer Research and the MD Anderson Cancer Center. He is also an Investment Advisory Partner at a16z Bio+Health, an Investment Advisory Board member at Droia Ventures, and an iPartner with The Column Group. He earned his B.A. in Molecular and Cell Biology in 2003 and Ph.D. in Molecular Toxicology in 2008 at UC Berkeley with Professor John Casida and was a postdoctoral fellow at Scripps Research with Professor Benjamin F. Cravatt before returning to Berkeley as a faculty member in 2011. Among his honors include the National Cancer Institute Outstanding Investigator Award, Searle Scholar, and the Mark Foundation for Cancer Research ASPIRE award.

## Major Research Directions

1. Chemoproteomics-enabled covalent ligand discovery platforms to tackle the undruggable proteome
2. Expanding the scope of targeted protein degradation using chemoproteomic platforms
3. Discovering new induced proximity-based therapeutic modalities

The Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to develop transformative medicines. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered "undruggable," in that most proteins do not possess known binding pockets or "ligandable hotspots" that small-molecules can bind to modulate protein function. Our research group addresses this challenge by advancing and applying chemoproteomic platforms to discover and pharmacologically target unique and novel ligandable hotspots for disease therapy. We currently have three major research directions. Our first major focus is on developing and applying chemoproteomics-enabled covalent ligand discovery approaches to rapidly discover small-molecule therapeutic leads that target unique and novel ligandable hotspots for undruggable protein targets and pathways. Our second research area focuses on using chemoproteomic platforms to expand the scope of targeted protein degradation technologies. Our third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to develop new induced proximity-based therapeutic modalities. Collectively, our lab is focused on developing next-generation transformative medicines through pioneering innovative chemical technologies to overcome challenges in drug discovery.

## Awards and Fellowships

2022	National Cancer Institute Outstanding Investigator Award
2019	Mark Foundation for Cancer Research ASPIRE award
2015	ACS Research Scholar Award
2015	DOD Breakthroughs Award Recipient
2013	Eicosanoid Research Foundation Young Investigator Award
2013	Hellman Fellows Awardee
2012	Searle Scholar Award
2010	NIH Pathway to Independence (PI) Award (K99/R00)
2009	American Cancer Society Postdoctoral Fellowship

## Affiliations

2024-current	Co-Director of the Molecular Therapeutics Initiative at UC Berkeley
2024-current	Scientific Advisory Board member of Deciphera Pharmaceuticals
2023-current	iPartner at The Column Group
2023-current	Scientific Advisory Board member of MD Anderson Cancer Center
2023-current	Investment Advisory Partner at a16z
2023-2023	Scientific Advisory Board member of Proravel Therapeutics
2023-current	Scientific Advisory Board member of Oerth Bio
2022-current	Droia Ventures Investment Advisory Board member
2022-current	Faculty in the Department of Molecular and Cell Biology, Molecular Therapeutics Division (UC Berkeley)
2022-2023	Director of the BMS-Berkeley Center for Chemical Biology and Therapeutics
2022-current	Director of the Amgen-Berkeley Chemoproteomics Center of Excellence
2022-current	Scientific Advisory Board member of Ecto Therapeutics
2022-current	Scientific Advisory Board member of Apertor Pharmaceuticals
2022-current	American Association for Cancer Research (AACR) Chemistry in Cancer Research Working Group Steering Committee member
2022-current	Founder, Chair of the Scientific Advisory Board, and Chair of the Board of Directors for Vicinitas Therapeutics (\$65 MM Series A funding)
2022-current	Associate Editor, Chemical Research in Toxicology
2021-current	Scientific Advisory Board member of Photys Therapeutics
2021-2022	Consultant for Droia Ventures
2021-current	Scientific Advisory Board member of Zenagem Therapeutics
2021-current	Editorial Board Member of Cell Chemical Biology
2021-current	Scientific Advisory Committee Member, Mark Foundation for Cancer Research
2020-current	Scientific Advisory Board for the Undruggables, Kisaco Research
2019-current	Investigator, Innovative Genomics Institute
2018-2021	Associate Editor of Cell Chemical Biology
2018-current	Editor of Current Protocols in Chemical Biology
2018-current	Co-Founder, Chair of the Scientific Advisory Board, and Consultant for Frontier Medicines (\$67 MM Series A funding, \$50 MM Abbvie partnership, \$89 MM Series B funding)
2018-current	Editorial Advisory Board for Chemical Research in Toxicology
2017-current	Director, Novartis-Berkeley Translational Chemical Biology Institute
2016-current	Member, UCSF Helen Diller Family Comprehensive Cancer Center
2016-current	Member, UCSF Breast Oncology Program
2016-2022	Faculty in the Department of Molecular and Cell Biology, Biochemistry, Biophysics, and Structural Biology Division (UC Berkeley)
2016-current	Adjunct Professor at UCSF, Department of Pharmaceutical Chemistry
2015-current	Faculty in the Department of Chemistry (UC Berkeley)
2015-2018	Adviser for 3-V Biosciences
2012-2019	Adviser for Abide Therapeutics (Acquired by Lundbeck Pharma in 2019)
2012-current	Member of the Synthetic Biology Institute (UC Berkeley)
2012-current	Member of the Center for Emerging and Neglected Diseases (UC Berkeley)
2012-current	Endocrinology Graduate Group (UC Berkeley)
2011-2022	Program in Metabolic Biology (UC Berkeley)
2011-current	Member of Chemical Biology Graduate Group (UC Berkeley)
2011-current	Member of Molecular Toxicology Graduate Group (UC Berkeley)
2011-2022	Member of Molecular and Biochemical Nutrition Graduate Group (UC Berkeley)
2011-2022	Faculty in the Department of Nutritional Sciences and Toxicology (UC Berkeley)

## Professional Associations

2004-current	American Chemical Society
2021-current	American Association for Cancer Research member
2004-2008	Society of Toxicology

## Academic Services

2024-current	Co-Director of the Molecular Therapeutics Initiative at UC Berkeley
2022-current	Director of the Amgen-Berkeley Chemoproteomics Center of Excellence
2022-2023	Director of the BMS-Berkeley Center for Chemical Biology and Therapeutics
2021	Member, Faculty selection committee for hiring in chemistry for the Department of Chemistry
2020-current	Molecular and Cell Biology graduate admissions committee member
2018-2019	NST space committee
2018	Cal Day NST Speaker
2018-2020	Miller Fellow Advisory Committee for the Department of Chemistry
2017-current	Director, Novartis-Berkeley Translational Chemical Biology Institute
2017-2021	Member, Animal Care and Use Committee
2017-2019	Member, College of Natural Resources Executive Committee
2017	Cal Day NST Speaker
2016-2017	Member, Faculty selection committee for hiring in cancer biology for the Molecular and Cell Biology department
2016-2017	Member, Faculty selection committee for hiring the next chair for the Nutritional Sciences and Toxicology department
2016-2017	Faculty adviser for Chemistry-Chemical Biology students
2016-2022	Member, Executive/Long Range Planning committee for Nutritional Sciences and Toxicology
2016-2017	Member, working group to advise on academic realignment as it pertains to the College of Natural Resources and the L&S Biological Sciences Division
2016-2021	Member, Committee for Laboratory and Environmental Biosafety
2014-current	Chair and Head Graduate Adviser, Molecular Toxicology Graduate Program
2014-2018	Member, CNR Student Faculty Relations Committee
2014	Member, Molecular and Cell Biology Cancer Faculty Search Committee
2014	Speaker for CalSO Faculty Showcase
2013-2017	Member, Metabolic Biology Graduate Affairs Committee
2012-current	Regents' and Chancellors' Scholarship Faculty Mentor
2012	Member, Faculty Selection committee for the Nutritional Sciences and Toxicology Department
2012-2017	Member, Seminar Speaker Selection Committee
2011-2018	Member, Undergraduate Affairs Committee for the Nutritional Sciences and Toxicology Department
2011-current	Member, Molecular Toxicology Graduate Affairs Committee

## Professional Academic Services

2024-current	Co-Director of the Molecular Therapeutics Initiative at UC Berkeley
2023-2024	Co-Chair for AACR Annual Meeting 2024 Program Committee
2023	Chair for the Bioorganic Chemistry Gordon Research Conference
2023-current	Scientific Advisory Board member of MD Anderson Cancer Center
2022-current	Standing Member for NIH Chemical Biology and Probes Study Section (CBP)
2022	Standing Member for NIH Synthetic and Biological Chemistry A Study Section (SBCA)
2022-current	Associate Editor for Chemical Research in Toxicology
2022	Vice Chair for Bioorganic Chemistry Gordon Research Conference
2021-2022	External Scientific Consultant for the National Cancer Institute Fusion Oncoproteins in Childhood Cancers (FuSOnc2) Program
2021-current	Scientific Advisory Committee Member, Mark Foundation for Cancer Research
2021-current	Editorial Board Member of Cell Chemical Biology
2018-2021	Editor of Cell Chemical Biology
2018-current	Editor of Current Protocols in Chemical Biology

2018-current	Editorial Advisory Board for Chemical Research in Toxicology
2018	Discussion Leader at 2018 Bioorganic Chemistry Gordon Research Conference, Andover, New Hampshire.
2018	Study section ad hoc member for Enabling Bioanalytical and Imaging Technologies (EBIT) study section
2018	Chair and organizer of EMBO meeting “Enzymes, biocatalysis and chemical biology: The new frontiers” Pavia, Italy.
2018	Chair and organizer of “Chemoproteomics and Metabolomics” session at 2018 ASBMB Experimental Biology meeting, San Diego
2017-2019	Study section ad hoc member for Cancer Drug Development & Therapeutics (CDDT) study section
2016	Study section ad hoc member for Recurring Special Emphasis Panel NIH ZRG1 BMCT-C(01) Molecular Targets and Cancer Intervention study section
2016	Study section member for Special Emphasis Panel NIH ZRG1 BSTU 50
2015	Editor for “Omics” Issue in Current Opinions in Chemical Biology
2011	Editor Special Issue for Biochimica Biophysica Acta (Lipids in Cancer)

**Reviewer for:** Cell, Molecular Cell, Cell Chemical Biology, Cell Metabolism, Cell Reports, Chemical Neurosciences, Chemical Reviews, Nature, Nature Chemical Biology, Nature Cell Biology, Chemical Sciences, PNAS, Biochimica et Biophysica Acta, Journal of the American Chemical Society, Nature Structural and Molecular Biology, Journal of Lipid Research, Journal of Clinical Investigation, Cancer and Metabolism, Molecular and Cellular Proteomics, ACS Chemical Biology, ACS Central Science, Journal of Biological Chemistry, eLife, Nature Chemistry

## Teaching

Fall 2023	UC Berkeley Instructor for Therapeutic Discovery and Development (MCB120)
Fall 2023	UC Berkeley Instructor for Research in Chemistry (Chem 96)
Fall 2022	UC Berkeley Instructor for Advanced Toxicology (NST110)
Fall 2022	UC Berkeley Instructor for Chemical Biology (Chem135)
Spring 2022	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2021	UC Berkeley Instructor for Freshman Seminar on: Chemical Biology as an Engine for Drug Discovery (Chem 24)
Fall 2021	UC Berkeley Instructor for
Spring 2021	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2021	UC Berkeley Instructor for Research in Toxicology (NST193)
Fall 2020	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2020	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2020	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2020	UC Berkeley Instructor for Advanced Seminar in MCB (MCB290)
Fall 2019	UC Berkeley Instructor for Advanced Toxicology (NST110)
Fall 2018	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2018	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2018	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2017	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2017	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2017	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2016	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2016	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2016	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2015	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2015	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2015	UC Berkeley Instructor for Research in Toxicology (NST193)
Fall 2014	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2014	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2013	UC Berkeley Instructor for Advanced Toxicology (NST110)

Spring 2013	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2012	UC Berkeley Instructor for Graduate Research Colloquium (NST292)
Spring 2012	UC Berkeley Instructor for Graduate Seminar (NST290): Chemical Approaches to Study Metabolism
Fall 2011	UC Berkeley Instructor for Undergraduate Special Seminar (NST190): “-Omic Approaches to Study Metabolism”
Spring 2007	UC Berkeley Lecturer for Molecular Toxicology (NST120)
Fall 2006	UC Berkeley Co-Instructor and Graduate Student Instructor for Advanced Toxicology (NST110)
Spring 2006	UC Berkeley Guest Lecturer for Pesticide Chemistry and Toxicology (ESPM148)
Spring 2006	UC Berkeley Lecturer for Molecular Toxicology (NST120)

## Publications

### 2024

1. Lim M\*, Do Cong T\*, Orr LM, Toriki ES, Kile AC, Lee E, **Nomura DK** (2024) DCAF16-based covalent handle for the rational design of monovalent degraders. *BioRxiv*.
2. Shihadih D, Wang X, Zushin P-JH, Khodakivskiy P, Park HM, Tso E, Shiblak J, Misic A, Louie SM, Ward C, Hellerstein M, **Nomura DK**, Goun E, Urigo F, Calvisi DF, Chen X, Stahl A (2024) FATP5 is indispensable for the growth of intrahepatic cholangiocarcinoma. *Molecular Cancer Research*, doi:10.1158/1541-7786.MCR-23-0389. PMID 38358323
3. Hong SH, Osa A, Huang OW, Wertz IE, **Nomura DK** (2024) Exploiting the Cullin E3 ligase adaptor protein SKP1 for targeted protein degradation. *ACS Chemical Biology*, <http://doi.org/10.1021/acscchembio.3c00642>. PMID 37904950
4. Meyers M, Cismoski S, Panidapu A, Chie-Leon B, **Nomura DK** (2024) Targeted protein degradation through recruitment of the CUL4A complex adaptor protein DDB1. *ACS Chemical Biology*, 19, 58-68. PMID 38192078

### 2023

5. Shao Q, Duong TN, Park I, **Nomura DK** (2023) Covalent 14-3-3 molecular glues and heterobifunctional molecules against nuclear transcription factors and regulators. *BioRxiv* doi: <https://doi.org/10.1101/2023.11.06.565850>.
6. Davis MA, Yu VY, Fu B, Wen M, Koleski EJ, Silverman J, Berdan CA, **Nomura DK**, Chang MCY (2023) A cellular platform for production of C4 monomers. *Chemical Science* 14, 11718-11726. PMID 37920356
7. Pham VN, Bruemmer KJ, Toh JDW, Ge EJ, Tenney L, Ward CC, Fingler FA, Millington CL, Garcia-Prieto CA, Pulos-Holmes MC, Ingolia NT, Pontel LB, Esteller M, Patel KJ, **Nomura DK**, Chang CJ (2023) Formaldehyde regulates S-adenosylmethionine biosynthesis and one-carbon metabolism. *Science* 382, doi: 10.1126/science.abp9201.
8. Gowans FA\*, Forte N\*, Hatcher J, Huang OW, Wang Y, Altamirano Poblano BE, Wertz IE, **Nomura DK** (2023) Covalent degrader of the oncogenic transcription factor  $\beta$ -catenin. *BioRxiv* doi: <https://doi.org/10.1101/2023.10.31.565018>. (\*co-first authorship)
9. Zhang L, Tang M, Tao X, Shao Q, Thomas V, Shimizu S, Kasano M, Ishikawa Y, Inukai T, **Nomura DK** (2023) Covalent targeting of glutamate cysteine ligase to inhibit glutathione synthesis. *Chembiochem*, doi: 10.1002/cbic.202300371. PMID 37756477
10. Toriki ES\*, Papatzimas JW\*, Nishikawa K, Dovala D, Frank AO, Hesse MJ, Dankova D, Song J-G, Bruce-Smythe M, Struble H, Garcia FJ, Brittain SM, Kile AC, McGregor LM, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2023) Rational chemical design of molecular glue degraders. *ACS Central Science*, 9, 915-926. PMID 37252349 (\* co-first authorship)
11. Gowans FA, Thach DQ, Wang Y, Altamirano Poblano BE, Dovala D, Tallarico JA, McKenna JM, Schirle M, Maimone TJ\*, **Nomura DK\*** (2023) Ophiobolin A covalently targets complex IV leading to mitochondrial metabolic collapse in cancer cells. *BioRxiv* doi: <https://doi.org/10.1101/2023.03.09.531918>.
12. King EA, Cho Y, Hsu NS, Dovala D, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2023) Chemoproteomics-Enabled Discovery of a Covalent Molecular Glue Degradar Targeting NF- $\kappa$ B. *Cell Chemical Biology*, 30, 394-402. PMID 36898369
13. Forte N, Dovala D, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2023) Targeted protein degradation through E2 recruitment. *ACS Chemical Biology*, 18, 897-904. PMID 36940189

14. Belcher BP, Ward CC, **Nomura DK** (2023) Ligandability of E3 ligases for targeted protein degradation applications. *Biochemistry* 62, 588-600. PMID 34473924
15. Moon P\*, Zammt CM\*, Shao Q\*, Dovala D\*, Boike L\*, Henning NJ\*, Knapp M\*, Spradlin JN\*, Ward CC\*, Wolleb H\*, Fuller D, Blake G, Murphy JP, Wang F, Lu Y, Moquin SA, Tandeske L, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, Toste FD<sup>#</sup>, **Nomura DK**<sup>#</sup> (2023) Discovery of potent pyrazoline-based covalent SARS-CoV-2 main protease inhibitors. *Chembiochem*, 24(11):e202300116. PMID 37069799 (\*co-first authors; #co-corresponding authors)
16. Belcher BP, Machicao PA, Tong B, Ho E, Friedli J, So B, Bui H, Isobe Y, Maimone TJ<sup>#</sup>, **Nomura DK**<sup>#</sup> (2023) Chemoproteomic Profiling Reveals that Anti-Cancer Natural Product Dankastatin B Covalently Targets Mitochondrial VDAC3. *Chembiochem*, doi: 10.1002/cbic.202300111. PMID 36964942 (#co-corresponding authors)
17. Bajaj T, Wehri E, Suryawanshi RK, King E, Pardeshi KS, Behrouzi K, Khodabakshi Z, Schulze-Gahmen U, Kumar GR, Mofrad MRK, **Nomura DK**, Ott M, Schaletzky J, Murthy N (2023) Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication. *RSC Advances*, 13, 17667-17677. PMID 37312993
18. Koo T-Y, Lai H, **Nomura DK**, Chung CY-K. (2023) *N*-acryloylindole-alkyne (NAIA) enables imaging and profiling new ligandable cysteines and oxidized thiols by chemoproteomics. *Nature Communications*, doi: <https://doi.org/10.1101/2023.05.18.541312>.
19. Han H, Gracia AV, Roise JJ, Boike L, Leon K, Schulze-Gahmen U, Stentzel MR, Bajaj T, Chen D, Li IC, He M, Behrouzi K, Khodabakshi Z, **Nomura DK**, Mofrad MRK, Kumar GR, Ott M, Murthy N. (2023) A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication. *RSC Advances*, 13, 10636-10641. PMID 37025664
20. Benjamin DI, Brett JO, Both P, Benjamin JS, Ishak HL, Kang J, Kim S, Chung M, Arjona M, Nutter CW, Tan JH, Krishnan AK, Dulay H, Louie SM, de Morree A, **Nomura DK**, Rando TA (2023) Multiomics reveals glutathione metabolism as a driver of bimodality during stem cell aging. *Cell Metabolism* 35, 472-486. PMID 36854304

## 2022

21. Henning NJ\*, Boike L\*, Spradlin JN, Ward CC, Liu G, Zhang E, Belcher BP, Brittain SM, Hesse M, Dovala D, McGregor LM, Veldez Misiolek R, Plasschaert LW, Rowlands DJ, Wang F, Frank AO, Fuller D, Estes AR, Randal KL, Panidapu A, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2022) Deubiquitinase-targeting chimeras for targeted protein stabilization. *Nature Chemical Biology* 18, 412-421. PMID 35210618 (\* co-first authorship)
22. Henning NJ\*, Manford AG\*, Spradlin JN, Brittain SM, McKenna JM, Tallarico JA, Schirle M, Rape M<sup>#</sup>, **Nomura DK**<sup>#</sup> (2022) Discovery of a covalent FEM1B recruiter for targeted protein degradation applications. *Journal of the American Chemical Society* 144, 701-708. PMID 34994556 (\*co-first authorship; #co-corresponding authorship)
23. Boike L\*, Henning NJ\*, **Nomura DK** (2022) Advances in covalent drug discovery. *Nature Reviews Drug Discovery* 21, 881-898. PMID 36008483 (\*co-first authors)
24. Shin HR, Citron YR, Wang L, Tribouillard L, Goul CS, Stipp R, Sugasawa Y, Jain A, Samson N, Lim C-Y, Davis OB, Castaneda-Carpio D, Qian M, **Nomura DK**, Perera RM, Park E, Covey DF, Laplante M, Evers AS, Zoncu R (2022) Lysosomal GPCR-like protein LYCHOS signals cholesterol sufficiency to mTORC1. *Science* 377, 1290-1298. PMID 36007018
25. Maza JC, Garcia-Almedina DM, Boike LE, Hamlisch NX, **Nomura DK**, Francis MB (2022) Tyrosinase-Mediated Synthesis of Nanobody-Cell Conjugates. *ACS Central Science* 8, 955-962. PMID 35912347
26. Benjamin DI, Both P, Benjamin JS, Nutter CW, Tan JH, Kang J, Machado LA, Klein JDD, de Morree A, Kim S, Liu L, Dulay H, Feraboli L, Louie SM, **Nomura DK**, Rando TA (2022) Fasting induces a highly resilient deep quiescent state in muscle stem cells via ketone body signaling. *Cell Metabolism* 34, 1-17. PMID 35584694
27. Page ACS, Scholz SO, Keenan KN, Spradlin JN, Belcher BP, Brittain SM, Tallarico JA, McKenna JM, Schirle M, **Nomura DK**\*, Toste FD\* (2022) Photo-Brook rearrangement of acyl silanes as a strategy for photoaffinity probe design. *Chemical Science* 13, 3851-3856. PMID 35432890 (\*co-corresponding author)

## 2021

28. Trauner D, Fischer C, Nynke V, Peitsinis Z, Ruhmann P, Yang C, Spradlin J, Dovala D, **Nomura D**, Zhang Y (2021) De novo design of SARS-CoV-2 Main Protease Inhibitors. *Synlett*, 33, 458-463. PMID 35282568

29. **Nomura DK**, Dey M (2021) Advances and opportunities in targeted protein degradation. *Cell Chemical Biology* 15, 887-888. PMID 34270936
30. Spradlin JN, Zhang E, **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. *Accounts of Chemical Research*. 54, 1801-1813. PMID 33733731
31. Luo M\*, Spradlin JN\*, Boike L, Tong B, Brittain SM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ#, **Nomura DK**#. (2021) Chemoproteomics-enabled ligand discovery of covalent RNF114-based degraders that mimic natural product function. *Cell Chemical Biology* 28, 559-566. PMID 33513350 (\*co-first authorship, # co-corresponding authorship)
32. Boike L\*, Cioffi AG\*, Majewski FC, Co J, Henning NJ, Jones MD, Liu G, McKenna JM, Tallarico JA, Schirle M, **Nomura DK**. (2021) Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. *Cell Chemical Biology* 28, 4-13. PMID 32966806 (\*co-first authorship)
33. Tong B, Belcher BP, **Nomura DK**, Maimone TJ (2021) Chemical investigations into the biosynthesis of the gymnastatin and dankastatin alkaloids. *Chemical Science* 12, 8884-8891. PMID 34257889
34. Biering SB, Van Dis E, Wehri E, Yamashiro LH, Nguyenla X, Dugast-Darzacq C, Graham TGW, Stroumza JR, Golovkine GR, Roberts AW, Fines DM, Spradlin JN, Ward CC, Bajaj T, Dovala D, Schulze Gahmen U, Bajaj R, Fox DM, Ott M, Murthy N, **Nomura DK**, Schaletzky J, Stanley SA (2021) Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2. *ACS Infectious Diseases* 7, 2337-2351. PMID 34129317
35. Kilinc S, Paisner R, Camarda R, Gupta S, Momcilovic O, Kohnz RA, L'Etoile ND, Perera RM, **Nomura DK**, Goga A (2021) Oncogene regulated release of extracellular vesicles. *Developmental Cell* 56, 1989-2006. PMID 34118203
36. Tharp KM, Higuchi-Sanabria R, Timblin GA, Ford B, Garzon-Coral C, Schneider C, Muncie JM, Stashko C, Daniele JR, Moore AS, Frankino PA, Homentcovschi S, Manoli SS, Shao H, Richards AL, Chen KH, Hoeve JT, Ku GM, Hellerstein M, **Nomura DK**, Saiko K, Gestwicki J, Dunn AR, Krogan NJ, Swaney DL, Dillin A, Weaver VM. (2021) Adhesion-mediated mechanosignaling forces mitohormesis. *Cell Metabolism* 33,1322-1341. PMID 34019840
37. Timblin GA, Tharp KM, Ford B, Winchenster JM, Wang J, Zhu S, Khan RI, Louie SK, Iavarone AT, ten Hoeve J, **Nomura DK**, Stahl A, Saijo K (2021) Mitohormesis reprograms macrophage metabolism to enforce tolerance. *Nature Metabolism* 3, 618-635. PMID 34031590
38. Moldavski O, Zushin P-JH, Berdan CA, Van Eijkeren RJ, Jiang X, Qian M, Ory DS, Covey SF, **Nomura DK**, Stahl A, Weiss EJ, Zoncu R (2021) 4 $\beta$ -hydroxycholesterol is a pro-lipogenic factor that promotes SREBP1c expression and activity through Liver X-receptor. *Journal of Lipid Research*, 62, 100051. PMID 33631213
39. Cho H, Shen Q, Zhang LH, Okumura M, Kawakami A, Ambrose J, Sigoillot F, Miller HR, Gleim S, Cobos-Correa A, Wang Y, Piechon P, Roma G, Eggiman F, Moore C, Aspesi Jr. P, Mapa FA, Burks H, Ross NT, Krastel P, Hild M, Maimone TJ, Fisher DE, **Nomura DK**, Tallarico JT, Canham SM, Jenkins JL, Forrester WC (2021) CYP27A1 dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. *Cell Chemical Biology* 28, 1407-1419. PMID 33794192
40. Tasic I, Heppler LN, Egusquiaguirre SP, Boehnke N, Correa S, Costa DF, Grossman EA, Pal S, Richardson D, Ivanov AR, Haas-Kogan DA, **Nomura DK**, Hammond PT, Frank DA (2021) Lipidome-based targeting of STAT3-driven breast cancer cells using poly-L-glutamic acid-coated layer-by-layer nanoparticles. *Molecular Cancer Therapeutics* 20, 726-738. PMID 33536189

## 2020

41. Isobe Y, Okumura M, White R, McGregor LM, Brittain SM, Jones MD, Liang X, White R, Forrester W, McKenna JM, Tallarico JA, Schirle M, Maimone TJ\*, **Nomura DK**\* (2020) Manumycin polyketides act as molecular glues between UBR7 and P53. *Nature Chemical Biology* 16, 1189-1198. PMID 3257277 (\*co-corresponding author)
42. Tong B\*, Spradlin JN\*, Novaes LFT, Zhang E, Hu X, Moeller M, Brittain SM, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ#, **Nomura DK**#. (2020) A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL. *ACS Chemical Biology* 15, 1788-1794. PMID 32568522 (\*co-first authorship; # co-corresponding authorship)
43. Tong B\*, Luo M\*, Xie Y, Spradlin JN, Tallarico JA, McKenna JM, Schirle M, Maimone TJ#, **Nomura DK**#. (2020) Bardoxolone Conjugation Enables Targeted Protein Degradation of BRD4. *Scientific Reports* 10, 15543. PMID 32968148 (\*co-first authorship; # co-corresponding authorship)



44. Manford AG, Rodriguez-Perez F, Shih KY, Shi Z, Berdan CB, Choe M, Titov DV, **Nomura DK**, Rape M (2020) A cellular mechanism to detect and alleviate reductive stress. *Cell* 183, 46-61. PMID 32941802
45. Sponton CH, Hosonoro T, Taura J, Jedrychowski MP, Yoneshiro T, Wang Q, Takahashi M, Matsui Y, Ikeda K, Oguri Y, Tajima K, Shinoda K, Pradham R, Chen Y, Brown Z, Roberts LS, Ward CC, Taoka H, Yokohama Y, Watanabe M, Karasawa H, **Nomura DK**, Kajimura S (2020) The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication. *EMBO Reports* 21, e49828. PMID 32672883
46. Ibars M, Maier MT, Yulyaningsih E, Perez L, Cheang R, Vihelmsson A, Louie SM, Wegner SA, Yuan X, Eltzschig HK, Hopf FW, **Nomura DK**, Koliwad SK, Xu AW (2020) Neuronal modulation of hepatic lipid accumulation induced by binge-like drinking. *American Journal of Physiology: Endocrinology and Metabolism* 318, E655-E666. PMID 32045262
47. Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, Shue YT, Ko JH, Lee MC, Kong C, **Nomura DK**, Ohlmeyer M, Swaney DL, Korgan N, Jackson PK, Narla G, Gordan JD, Shokat K, Sage J (2020) Unbiased proteomic profiling uncovers a targetable GNAS/PKA/PP2A axis in small cell lung cancer stem cells. *Cancer Cell* 38, 129-143. PMID 32521271

## 2019

48. Chung CY-S\*, Shin HR\*, Berdan CA, Ford B, Ward CC, Olzmann JA, Zoncu R#, **Nomura DK**# (2019) Covalent targeting of the vacuolar H<sup>+</sup>-ATPase activates autophagy via mTORC1 inhibition. *Nature Chemical Biology* 15, 776-785. PMID 31285595 (\*co-first authorship; #co-corresponding authorship)
49. Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L, To M, Proudfoot A, Ornelas E, Woldegiorgis M, Olzmann JA, Bussiere DE, Thomas JR, Tallarico JA, McKenna JM, Schirle M, Maimone TJ\*, **Nomura DK**\* (2019) Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. *Nature Chemical Biology* 15, 747-755. PMID 31209351 (\*co-corresponding authors)
50. Ward CC, Kleinman JI, Chung CYS, Kim K, Petri Y, Lee PS, Thomas JR, Tallarico JA, McKenna JM, Schirle M, **Nomura DK** (2019) Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications. *ACS Chemical Biology* 14, 2430-2440. PMID 31059647
51. Berdan CA, Ho R, Lehtola HS, To M, Hu X, Huffman TR, Petri Y, Altobelli CR, Demeulenaere SG, Olzmann JA, Maimone TJ\*, **Nomura DK**\* (2019) Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells. *Cell Chemical Biology* 26, 1027-1035. PMID 31080076 (\*co-corresponding authorship)
52. Ah Yong V, Berdan CA, Burke TP, **Nomura DK**, Welch MD (2019) A metabolic dependency for host isoprenoids in the obligate intracellular pathogen *Rickettsia parkeri* underlies a sensitivity to the statin class of host-targeted therapeutics. *mSphere* 4 (6), e00536-19. PMID 31722991
53. Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, **Nomura DK**, Dixon SJ, Olzmann JA (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* 575, 688-692. PMID 31634900
54. Lim C-Y, Davis O, Shin H, Zhang J, Berdan CB, Jiang X, Counihan JL, Ory D, Nomura DK, Zoncu R (2019) ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signaling in Niemann-Pick type C. *Nature Cell Biology* 21, 1206-1218. PMID 31548609
55. Lee K, Yesilkanal AE, Wynne JP, Frakenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P, Grossman EA, Hart PC, Kang C, Sanderson SM, Andrade J, **Nomura DK**, Bonini MG, Locasale JW, Rosner MR (2019) Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. *Nature* 568, 254-258. PMID 30842661
56. Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjana B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayarathne PR, Matzaris M, Montgomer MK, Pargargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, **Nomura DK**, Taylor RA. (2019) Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. *Science Translational Medicine* 11(478):eaau5758. PMID 3078288
57. Herber CB, Krause WC, Wang L, Bayrer JR, Li A, Schmitz M, Fields A, Ford B, Zhang Z, Reid MS, **Nomura DK**, Nissenson RA, Correa SM, Ingraham HA (2019) Estrogen signaling in arcuate *Kiss1* neurons suppresses a sex-dependent female circuit promoting dense strong bones. *Nature Communications*, 10, 163. PMID 30635563

58. Magtanong L, Ko P-J, To M, Cao JY, Tarangelo AN, Ward CC, Cho KY, Patti GJ, **Nomura DK**, Olzmann JA, Dixon SJ (2019) Exogenous monounsaturated fatty acids suppress non-apoptotic cell death. *Cell Chemical Biology* 26, 420-432. PMID 30686757
59. Stazi G, Battistelli C, Piano V, Mazzone R, Marrocco B, Marchese S, Louie SM, Zwergel C, Antonini L, Patsilnakos A, Ragno R, Viviano M, Sbardella G, Ciogli A, Fabrizi G, Cirilli R, Strippoli R, Marchetti A, Tripodi M, **Nomura DK**, Mattevi A, Mai A, Valente S (2019) Development of alky glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-to-mesenchymal transition in cancer cells. *European Journal of Medicinal Chemistry* 163, 722-735. PMID 30576903
60. Volkmar N, Thezenas M-L, Louie SM, Juszkievicz S, **Nomura DK**, Hegde RS, Kessler BM, Christianson JC (2019) The ER membrane protein complex (EMC) promotes biogenesis of sterol-related enzymes maintaining cholesterol homeostasis. *Journal of Cell Science* 132, pii:jcs223453. PMID 30578317

## 2018

61. **Nomura DK** (2018) Virtual Issue on the Work of John Casida. *Chemical Research in Toxicology* 31, 637-638. PMID 30080400
62. **Nomura DK\*** and Maimone TJ\*. (2018) Target identification of bioactive covalently-acting natural products. *Current Topics in Microbiology and Immunology* 420, 351-374. PMID 30105423 (\*co-corresponding authorship)
63. Counihan JL\*, Wiggernhorn A\*, Anderson KE, **Nomura DK**. (2018) Chemoproteomics-enabled covalent ligand screening reveals ALDH3A1 as a lung cancer target. *ACS Chemical Biology* 13, 1970-1977. (\*co-first authors) PMID 300004670
64. Counihan JL, Grossman EA, **Nomura DK**. (2018) Cancer metabolism: current understanding and therapies. *Chemical Reviews* 118, 6893-6923. PMID 29939018
65. Long JZ, Roche AM, Berdan CA, Louie SM, Roberts AJ, Svensson KJ, Dou FY, Bateman LA, Mina AI, Deng Z, Jedrychowski MP, Lin H, Kamenecka T, Asara JM, Griffin PR, Banks AS, **Nomura DK**, Spiegelman BM. (2018) Ablation of PM20D1 reveals N-acyl amino acid control of metabolism and nociception. *Proceedings of the National Academy of Sciences, U.S.A.* 115, E6937-E6945. PMID 29967167
66. Fernandez RF, Kim SQ, Zhao Y, Foguth RM, Weera MM, Counihan JL, **Nomura DK**, Chester JA, Cannon JR, Ellis JM (2018) Acyl-CoA synthetase 6 enriches the neuroprotective omega-3 fatty acid DHA in the brain. *Proceedings of the National Academy of Sciences, U.S.A.* 115, 12525-12530. PMID 30327559
67. Zhou M, Ford B, Lee D, Huen K, Tran Y, Bradman A, Gunier R, Eskenazi B, **Nomura DK**, Holland NT (2018) Metabolomic markers of phthalate exposure in plasma and urine of pregnant women. *Frontiers in Public Health* 6, 298. PMID 30406068
68. Wallace M, Green CR, Roberts LS, Lee YM, McCarville J, Sanchez-Gurmaches J, Meurs N, Gengatharan JM, Hover J, Phillips SA, Ciaraldi TP, Guertin DA, Cabrales P, Ayres JS, **Nomura DK**, Loomba R, Metallo CM (2018) Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissue. *Nature Chemical Biology* 14, 1021-1031. PMID 30327559
69. Van Daltsen KM, Hodapp S, Keskin A, Otto GM, Berdan CA, Higdon A, Cheunkarndee T, **Nomura DK**, Jovanovic M, Brar GA. (2018) Global proteome remodeling during ER stress involves Hac1-driven expression of long undecoded transcript isoforms. *Developmental Cell* 46, 219-235. PMID 30016623
70. Tam AB, Roberts LS, Chandra V, Rivera IG, **Nomura DK**, Forbes DJ, Niwa M. (2018) The UPR activator ATF6 responds to proteotoxic and lipotoxic stress by distinct mechanisms. *Developmental Cell* 46, 327-343. PMID 30086303
71. Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, Sreaton RA, Sakamoto K, Ryan DP, Mino-Kenudson M, Fernandez-del Castillo C, **Nomura DK**, Haas W, Bardeesy N. (2018) Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. *Nature Cell Biology* 20, 811-822. PMID 29941929
72. Maier MT, Vilhelmsson A, Louie SM, Vagena E, **Nomura DK**, Koliwad SK, Xu AW. (2018) Regulation of hepatic lipid accumulation and distribution by Agouti-related protein in male mice. *Endocrinology* 159, 2408-2420. PMID 29750244
73. Lin H, Long JZ, Roche AM, Svensson KJ, Dou F, Chang MR, Sruzenberg T, Ruiz C, Cameron MD, Novick SJ, Berdan CA, Louie SM, **Nomura DK**, Spiegelman BM, Griffin PR, Kamenecka TM. (2018) Discovery of hydrolysis-resistant isoindoline N-acyl amino acid analogs that stimulate mitochondrial respiration. *Journal of Medicinal Chemistry* 61, 3224-3230. PMID 29533650

74. Tomin T, Fritz K, Gindlhuber J, Waldherr L, Pucher B, Thallinger GG, **Nomura DK**, Schittmayer M, Birner-Gruenberger R. (2018) Deletion of adipose triglyceride lipase links triacylglycerol accumulation to a more aggressive phenotype in A549 lung carcinoma cells. *Journal of Proteome Research* 17, 1415-1425. PMID 29457907
75. Prasse C, Ford B, **Nomura DK**, Sedlak DL. (2018) Unexpected transformation of dissolved phenols to toxic dicarbonyls by hydroxyl radicals and UV light. *Proceedings of the National Academy of Sciences, USA*. 115, 2311-2316. PMID 29463747
76. Nnadi CI, Jenkins ML, Gentile DR, Bateman LA, Zaidman D, Ballus TE, **Nomura DK**, Burke JE, Shokat KM, London N. (2018) Novel K-Ras G12C switch-II covalent binders destabilize Ras and accelerate nucleotide exchange. *Journal of Chemical Information and Modeling* 57, 464-471. PMID 29320178
77. Gibeaux R, Acker R, Kitaoka M, Georgiou G, van Kruijsbergen I, Ford B, Marcotte EM, **Nomura DK**, Kwon T, Veenstra GJC, Heald R. (2018) Paternal chromosome loss and metabolic crisis contribute to hybrid inviability in *Xenopus*. *Nature* 553, 337-341. PMID 29320479
78. Bersuker K, Peterson CWH, To M, Sahl SJ, Savikhin V, Grossman EA, **Nomura DK**, Olzmann JA. (2018) A proximity labeling strategy provides insights into the composition and dynamics of lipid droplet proteomes. *Developmental Cell* 44, 97-112. PMID 29275994

## 2017

79. Lue JW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburgh KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, **Nomura DK**, Drake JM, Ritz A, Thomas GV. (2017) Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. *Genes and Development* 31, 2067-2084. PMID 29138276
80. De Leon JA, Qiu J, Nicolai CJ, Counihan JL, Barry KC, Xu L, Lawrence RE, Castellano BM, Zoncu R, **Nomura DK**, Luo Z-Q, Vance RE. (2017) Positive and negative regulation of the master metabolic regulator mTORC1 by two families of *Legionella pneumophila* effectors. *Cell Reports* 21, 2031-2038. PMID 29166595
81. Grossman E\*, Ward CC\*, Spradlin JN, Bateman LA, Huffman TR, Miyamoto DK, Kleinman JI, **Nomura DK**. (2017) Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products. *Cell Chemical Biology* 24, 1368-1376. PMID 28919038 (\*co-first authorship)
82. Anderson KE, To M, Olzmann JA, **Nomura DK**. (2017) Chemoproteomics-enabled covalent ligand screening reveals a thioredoxin-caspase 3 interaction disruptor that impairs breast cancer pathogenicity. *ACS Chemical Biology* 12, 2522-2528. PMID 28892616
83. Chen T-C, Benjamin DI, Kuo T, Lee RA, Li M-L, Mar D, Costello DE, **Nomura DK**, Wang J-C. (2017) Glucocorticoid-Angiopoietin-like 4-Ceramide Axis induces insulin resistance. *Science Signaling* 10, eaai7905. PMID 28743803
84. Chomvong K, Benjamin DI, **Nomura DK**, Cate JH. Cellobiose consumption uncouples extracellular glucose sensing and glucose metabolism in *Saccharomyces cerevisiae*. *mBio* 8, e00855-17.
85. Nguyen TB, Louie SM, Daniele J, Tran Q, Dillin A, Zoncu R, **Nomura DK**, Olzmann JA. (2017) DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy. *Developmental Cell* 42, 9-21. PMID 28697336
86. Ward CC, Kleinman J, **Nomura DK**. (2017) NHS-esters as versatile reactivity-based probes for mapping proteome-wide ligandable hotspots. *ACS Chemical Biology* 12, 1478-1483. PMID 28445029
87. Bateman LA#, Nguyen TB#, Roberts AM#, Miyamoto DK, Ku W-M, Huffman TR, Petri Y, Heslin MJ, Contreras CM, Skibola CF, Olzmann JA\*, **Nomura DK\***. (2017) Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in Reticulon 4 that impairs ER morphology and cancer pathogenicity. *Chemical Communications* 53, 7234-7237. PMID 28352901 (#co-first authors; \*co-corresponding author)
88. Roberts LS, Yan P, Bateman LA, **Nomura DK**. (2017) Mapping novel metabolic nodes targeted by anti-cancer drugs that impair triple-negative breast cancer pathogenicity. *ACS Chemical Biology* 12, 1133-1140. PMID 28248089
89. Bateman LA, Ku W-M, Heslin MJ, Contreras CM, Skibola CF, **Nomura DK**. (2017) ASS1 is an important metabolic regulator of colorectal cancer. *ACS Chemical Biology* 12, 905-911. PMID 28229591
90. Castellano, B.M., Thelen, A.M., Moldavski O, Feltes M, van der Welle R, Mydock-McGrane L, Jiang X, van Eijkeren RJ, Davis OB, Louie SM, Perera RM, Covey D, **Nomura DK**, Ory DS, Zoncu R. (2017) Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann Pick C1 signaling complex. *Science* 355, 1306-1311. PMID 28336668

91. Roberts AM, Miyamoto DK, Huffman TR, Bateman LA, Ives AN, Akopian D, Heslin MJ, Contreras CM, Rape M, Skibola CF, **Nomura DK**. (2017) Chemoproteomic screening of covalent ligands reveals UBA5 as a novel pancreatic cancer target. *ACS Chemical Biology* 12, 899-904. PMID 28186401
92. Counihan JL, Duckering M, Dalvie E, Ku W-m, Bateman LA, Fisher KJ, **Nomura DK**. (2017) Mapping proteome-wide reactivity of the widely used herbicide acetochlor in mice. *ACS Chemical Biology* 12, 635-642. PMID 28094496
93. Whang MI, Taveras RM, Benjamin DI, Kattah MG, Advincula R, **Nomura DK**, Debnath J, Malynn BA, Ma A. (2017) The ubiquitin binding protein TAX1BP mediates autophagosome induction and the metabolic transition of activated T cells. *Immunity* 46, 405-420. PMID 28314591
94. Anderton B, Camarda R, Balkrishnan S, Balakrishnan A, Kohnz RA, Lim L, Evason KJ, Momcilovic O, Kruttwig K, Huang Q, Xu G, **Nomura DK**, Goga A. (2017) MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. *EMBO Report* 18, 569-585. PMID 28219903
95. Ford B, Bateman LA, Gutierrez-Palominos L, Park R, **Nomura DK**. (2017) Mapping proteome-wide targets of glyphosate in mice. *Cell Chemical Biology* 24, 133-140. PMID 28132892
96. Ruby MA, Massart J, Hunerdosse DM, Schonke M, Correia JC, Louie SM, Ruas JL, Naslund E, **Nomura DK**, Zierath JR. (2017) Human carboxylesterase 2 reverses obesity-induced diacylglycerol accumulation and glucose intolerance. *Cell Reports* 18, 636-646. PMID 28099843
97. Roberts AM, Ward CC, **Nomura DK**. (2017) Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots. *Current Opinion in Biotechnology* 43, 25-33. PMID 27568596
98. To M, Peterson CWH, Roberts MA, Counihan JL, Wu TT, Forster MS, **Nomura DK**, Olzmann JA. (2017) Lipid disequilibrium disrupts ER proteostasis by impairing ERAD substrate glycan trimming and dislocation. *Molecular Biology of the Cell* 28, 270-284. PMID 27881664

## 2016

99. Kim H-E, Grant AR, Simic MS, Kohnz RA, **Nomura DK**, Durieux J, Riera CE, Sanchez M, Kapernick E, Wolff Suzanne, Dillin A (2016) Lipid biosynthesis coordinates a mitochondrial-to-cytosolic stress response. *Cell* 166, 1539-1552. PMID 27568596
100. Sogi K, Holsclaw C, Fragiadakis G, **Nomura DK**, Leary J, Bertozzi C. (2016) Biosynthesis and regulation of sulfomenaquinone, a metabolite associated with virulence in Mycobacterium tuberculosis. *ACS Infectious Diseases* 2, 800-806. PMID 27933784
101. Braverman J, Sogi KM, Benjamin D, **Nomura DK**, Stanley SA. (2016) HIF-1alpha is an essential mediator of IFA-gamma-dependent immunity to Mycobacterium tuberculosis. *Journal of Immunology* doi: 10.4049/jimmunol.1600266. PMID 27430718
102. Kohnz RA, Roberts, LS, DeTomaso D, Badyopadhyay S, Yosef N, **Nomura DK**. (2016) Protein sialylation regulates a gene expression signature that promotes breast cancer cell pathogenicity. *ACS Chemical Biology* 11, 2131-2139. PMID 27380425
103. Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, Lou J, Rao RR, Chang MT, Jedrychowski MP, Paolo J, Griffin PR, **Nomura DK\***, Spiegelman BM\* (2016) PM20D1 secretion by thermogenic adipose cells regulates lipidated amino acid uncouplers of mitochondrial respiration. *Cell* 166, 424-435. PMID 27374330 (\*co-corresponding authorship)
104. Chomvong K, Bauer S, Benjamin DI, Li X, **Nomura DK**, Cate JHD. (2016) Bypassing the pentose phosphate pathway: Towards modular utilization of xylose. *Plos One* 11, e0158111. PMID 27336308
105. Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, **Nomura DK**. (2016) GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. *Cell Chemical Biology* 5, 567-578. PMID 27185638
106. Zhang J, Medina-Cleghorn D, Bernal-Mizrachi L, Bracci PM, Hubbard A, Conde L, Riby J, **Nomura DK**, Skibola C (2016) The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. *Oncoscience* 3, 31-41. PMID 26973858
107. Nikkanen J, Forsstrom S, Euro L, Paetau I, Kohnz RA, Wang L, Chilov D, Viinamaki J, Roivainen A, Marjamaki P, Liljenback H, Ahola S, Buzkova J, Terzioglu M, Khan NA, Pirnes-Karhu S, Paetau A, Lonqvist T, Sajantila A, Isohanni P, Tynnaismaa H, **Nomura DK**, Battersby B, Velagapudi V, Carroll CJ, Suomalainen A (2016) Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. *Cell Metabolism* 23, 635-648. PMID 26924217
108. **Nomura DK**, Casida JE (2016) Lipases and their inhibitors in health and disease. *Chemico-Biological Interactions* 259, 211-222. PMID 27067293

109. Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, **Nomura DK**, Goga A. (2016) Inhibition of fatty-acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. *Nature Medicine* 22, 427-432. PMID 26950360.
110. Saghatelian A, **Nomura DK**, Weerapana E (2016) Omics: The maturation of chemical biology. *Current Opinions in Chemical Biology* 30: v-vi. PMID 26739665
111. Counihan JC, Ford B, **Nomura DK**. (2016) Mapping Proteome-Wide Interactions of Reactive Chemicals using Chemoproteomic Platforms. *Current Opinions in Chemical Biology* 30, 68-76. PMID 26647369

## 2015

112. Medina-Cleghorn D, Bateman LA, Ford B, Heslin A, Fisher KJ, Dalvie ED, **Nomura DK**. (2015) Mapping proteome-wide targets of environmental chemicals using reactivity-based chemoproteomic platforms. *Chemistry and Biology* 22, 1394-1405. PMID26496688
113. Piano V<sup>#</sup>, Benjamin DI<sup>#</sup>, Valente S, Nenci S, Mai A, Aliverti A, **Nomura DK\***, Mattevi A\*. (2015) Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents. *ACS Chemical Biology* 10, 2589-2597. PMID 26322624 (<sup>#</sup>co-first authors; \* co-corresponding authors).
114. Queiroz A, Medina-Cleghorn D, Marjanovic O, **Nomura DK**, Riley LW. (2015) Comparative metabolic profiling of *Mycobacterium tuberculosis*: cell wall lipid reorganization as a virulence factor. *Pathogens and Disease* 73, ftv066. PMID26319139.
115. Sanchez-Alavez M, Nguyen W, Mori S, Moroncini G, Viader A, **Nomura DK**, Cravatt BF, Conti B. (2015) Monoacylglycerol lipase regulates fever response. *Plos One* 10, e0134437. PMID: 26287872.
116. Kohnz RA, Mulvihill MM, Chang JW, Hsu K-L, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, **Nomura DK**. (2015) Activity-based protein profiling of oncogene-driven changes in metabolism reveals PAFAH1B2 and 1B3 as broad-spectrum cancer therapy targets. *ACS Chemical Biology* 10, 1624-1630. PMID: 25945974.
117. Benjamin DI, Li DS, Lowe, W, Heuer T, Kemble G, **Nomura DK**. (2015) Diacylglycerol metabolism and signaling is a predictive and driving force underlying FASN inhibitor sensitivity in cancer cells. *ACS Chemical Biology* 10, 1616-1623. PMID: 25871544
118. Rashidian J, Le Scolan E, Ji X, Mulvihill MM, **Nomura DK**, Luo K. (2015) Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. *Science Signaling* 10, ra14. PMID: 25670202
119. Anderson CM, Kazantzis M, Wang J, Venkatraman S, Goncalves RLS, Quinlan CL, Ng R, Jastroch, M, Benjamin DI, Nie B, Herber C, Van A-AN, Park MK, Yun D, Chan K, Yu A, Vuong P, Febbraio M, **Nomura DK**, Napoli JL, Brand MD, Stahl A. (2015) Dependence of brown adipose tissue function on CD36-mediated coenzyme Q uptake. *Cell Reports* 10, 505-515. PMID 25620701
120. Chang JW, Zuhl AM, Speers AE, Niessen S, Brown SJ, Mulvihill MM, Fan YC, Spicer TP, Southern M, Scampavia L, Fernandez-Vega V, Dix MM, Cameron MD, Hodder PS, Rosen H, **Nomura DK**, Kwon O, Hsu K-L, Cravatt BF. (2015) A selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. *ACS Chemical Biology* 10, 925-932. PMID: 25602368

## 2014

121. Lysenko LV, Kim J, Henry C, Tyrtysnaia A, Kohnz RA, Madamba F, Simon GM, Kleschevnikova NE, **Nomura DK**, Ezekowitz RAB, Kleschevnikov AM. (2014) Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in aged Ts65Dn mice, a model of Down Syndrome. *Plos One* 9, e114521. PMID: 25474204.
122. Valdearcos M, Robblee M, Benjamin DI, **Nomura DK**, Xu AW, Koliwad SK. (2014) Microglia Dictate the Impact of Saturated Fat Consumption on Hypothalamic Inflammation and Neuronal Function. *Cell Reports* 9, 1-15. PMID: 25497089
123. Hunerdosse D, Morris PJ, Miyamoto DK, Fisher KJ, Bateman LA, Ghazaleh J, Zhong S, **Nomura DK**. (2014) Chemical Genetics Screening Reveals KIAA1363 as a Cytokine-Lowering Target. *ACS Chemical Biology* 9, 2905-2913. PMID: 25343321.
124. Medina-Cleghorn D, **Nomura DK**. (2014) Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platforms. *Chemistry & Biology* 21, 1171-1184. PMID: 25237861.
125. Mulvihill MM, **Nomura DK**. (2014) Metabolomic Strategies to Map Functions of Metabolic Pathways. *AJP Metabolism and Endocrinology* 307, E237-E244. PMID: 24918200

126. Latimer LN, Lee MR, Medina-Cleghorn D, Kohnz RA, **Nomura DK**, Dueber JE. (2014) Employing a combinatorial expression approach to characterize xylose utilization in *Saccharomyces cerevisiae*. *Metabolic Engineering* 25, 20-29. PMID: 24930894.
127. Mulvihill MM, Benjamin DI, LeScolan E, Ji X, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, **Nomura DK**. (2014) Metabolic Profiling Reveals PFAH1B3 as a critical driver of breast cancer pathogenicity. *Chemistry & Biology* 21, 831-840. PMID: 24954006
128. Benjamin DI, Louie S, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A, Bandhyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng-SW, **Nomura DK**. (2014) Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. *ACS Chemical Biology* 20, 1340-1350. PMID: 24738946
129. Kohnz RK, **Nomura DK**. (2014) Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. *Chemical Society Reviews* 43, 6859-6869. PMID: 24676249
130. Morris PJ\*, Medina-Cleghorn D\*, Heslin A, King S, Orr J, Krauss RM, **Nomura DK**. (2014) Organophosphorus flame retardants inhibit specific liver carboxylesterases and cause serum hypertriglyceridemia. *ACS Chemical Biology* 9, 1097-1103. (\*authors contributed equally to the work) PMID: 24597639
131. Hunerdosse D, **Nomura DK**. (2014) Activity-based proteomic and metabolomic approaches for understanding metabolism. *Current Opinion in Biotechnology* 28C, 116-126. PMID 24594637
132. Poole D, Lee M, Tso P, Bunnett N, Yo S, Lieu T, Shiu A, Wang J-C, **Nomura DK**, and Aponte GW. (2014) Feeding dependent activation of enteric cells and sensory neurons by lymphatic fluid: evidence for a neurolymphocrine system. *AJP-Gastrointestinal and Liver Physiology* 306, G686-G698. PMID: 24578341
133. Dominguez E, Galmozzi A, Chang JW, Hsu K-L, Pawlak J, Li W, Godio C, Thomas J, Partida D, Niessen S, O'Brien PE, Russell AP, Watt MJ, **Nomura DK**, Cravatt BF, Saez E. (2014) Integrated phenotypic screening and activity-based proteomics defines a role for carboxylesterase 3 in obesity and diabetes. *Nature Chemical Biology* 10, 113-121. PMID: 24362705
134. Medina-Cleghorn D, Heslin A, Morris PJ, Mulvihill MM, **Nomura DK**. (2014) Multidimensional profiling platforms reveal metabolic dysregulation caused by organophosphorus pesticides. *ACS Chemical Biology* 9, 423-432. PMID: 24205821

## 2013

135. **Nomura DK**, Cravatt BF. (2013) Lipid Metabolism in Cancer. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1497-1498. PMID: 23921253
136. Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Luo K, **Nomura DK**. (2013) The ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids that fuel cancer pathogenicity. *Proceedings of the National Academy of Sciences, USA* 110, 14912-14917. PMID: 23980144
137. Louie SM\*, Roberts LS\*, Mulvihill MM, Luo K, **Nomura DK**. (2013) Cancer cells incorporate and remodel exogenous fatty acids into structural and oncogenic signaling lipids. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1566-1572. PMID: 23872477 (\* authors contributed equally to the work)
138. Louie SM, Roberts LS, **Nomura DK**. (2013) Mechanisms linking obesity and cancer. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1499-1508. PMID: 23470257
139. Medina-Cleghorn D, **Nomura DK**. (2013) Chemical Approaches to Study Metabolic Networks. *Pflugers Archive* 465,427-440. PMID: 23296751
140. Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdelyi K, Hao E, Holovac E, Hasko G, Cravatt BF, **Nomura DK**<sup>#</sup>, Pal Pacher<sup>#</sup>. (2013) Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. *Gastroenterology* 144, 808-817. PMID: 23295443 (# co-corresponding authors)
141. Mulvihill MM, **Nomura DK**. (2013) Therapeutic Potential of Monoacylglycerol Lipase Inhibitors. *Life Sciences* 92, 492-497. PMID: 23142242

## 2012

142. Morrison BE, Garibaldi Marcondes MC, **Nomura DK**, Sanchez-Alavez M, Saar I, Bartfai T, Maher P, Sugama S, Conti B. (2012) IL-13R $\alpha$ 1 expression in dopaminergic neurons contributes to their oxidative

stress-mediates loss following chronic systemic treatment with LPS. *Journal of Immunology* 189, 5498-5502. PMID: 23169588

143. Benjamin DI, Cravatt BF, **Nomura DK**. (2012) Global Profiling Strategies towards Mapping Dysregulated Metabolic Pathways in Cancer. *Cell Metabolism* 16, 565-567. PMID: 23063552
144. Piro JR, Benjamin DI, Duerr JM, Pi YQ, Gonzales C, Schwartz JW, **Nomura DK**<sup>#</sup>, Samad TA<sup>#</sup>. (2012) A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer's Disease. *Cell Reports* 1, 617-623. PMID: 22813736 (# co-corresponding author)

## 2011

145. **Nomura DK**<sup>#</sup>, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF<sup>#</sup>. (2011) Endocannabinoid hydrolysis generates brain eicosanoids that promote neuroinflammation. *Science* 334, 809-813. PMID: 22021672 (# co-corresponding author)
146. Ruby MA, **Nomura DK**, Hudak CSS, Barber A, Casida JE, Krauss RM. (2011) Overactive endocannabinoid signaling induces hepatic steatosis, insulin resistance, and global transcriptional changes. *Plos One* 6, e26415. PMID: 22073164

## Undergraduate/Graduate/Postdoctoral Work (2002-2011)

147. **Nomura DK**<sup>#</sup>, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, Hoover HH, Cravatt BF<sup>#</sup>. (2011) Monoacylglycerol lipase exerts bidirectional control over endocannabinoid and fatty acid pathways to support prostate cancer pathogenesis. *Chemistry & Biology* 18, 848-856. PMID: 21802006 (# co-corresponding author)
148. Ramesh D, Ross GR, Schlosburg JE, Abdullah RA, Kinsey SG, Long JZ, **Nomura DK**, Sim-Selley LJ, Cravatt BF. (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated withdrawal symptoms in mice. *Journal of Pharmacology and Experimental Therapeutics* 339, 173-185. PMID: 21719468
149. Kinsey SG, **Nomura DK**, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. (2011) Inhibition of monoacylglycerol lipase (MAGL) attenuates NSAID-induced gastric hemorrhages in mice. *Journal of Pharmacology and Experimental Therapeutics* 338, 795-802. PMID: 21659471
150. Chang JW, **Nomura DK**, Cravatt BF. (2011) A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. *Chemistry & Biology* 18, 476-484. PMID: 21513884
151. Ahn K, Smith SE, Liimata MB, Sadagopan N, Dudley D, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, **Nomura DK**, Bhattachar SN, Stif C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. (2011) Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain. *Journal of Pharmacology and Experimental Therapeutics* 338, 114-124. PMID: 21505060
152. **Nomura DK**<sup>#</sup>, Casida JE<sup>#</sup>. (2011) Activity-based protein profiling of organophosphorus and thiocarbamate pesticides reveals multiple secondary targets in the mammalian nervous system. *Journal of Agricultural and Food Chemistry* 59, 2808-2815. PMID: 21341672 (# co-corresponding author)
153. Nicolaou KC, Sanchini S, Sarlah D, Lu G, Wu R, **Nomura DK**, Cravatt BF, Cubitt B, de la Torre JC, Hessell AJ, Burton DR. (2011) Design, synthesis and biological evaluation of a biyouyanagin compound library. *Proceedings of the National Academy of Sciences, USA* 108, 6715-6720. PMID: 21245351
154. Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Schürer, **Nomura DK**, Rosen H, Fu GC, Cravatt BF. (2011) Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. *Proceedings of the National Academy of Sciences, USA* 108, 6811-6816. PMID: 21398589
155. Kopp F, Komatsu T, **Nomura DK**, Trauger SA, Thomas JR, Simon GM, Cravatt BF. (2010) The glycerophospho-metabolome and its influence on amino acid homeostasis by brain metabolomics of GDE1(-/-) mice. *Chemistry & Biology* 17, 831-840. PMID: 20797612
156. Schlosburg JE, Blankman JL, Long JZ, **Nomura DK**, Nguyen PT, Ramesh D, Kinsey SG, Booker L, Burston JK, Wise LE, Ghosh S, Selley DE, Sim-Selley LJ, Liu Q, Cravatt BF, Lichtman AH. (2010) Sustained inactivation of monoacylglycerol lipase produces functional antagonism of the brain endocannabinoid system. *Nature Neuroscience* 13, 1113-1119. PMID: 20729846
157. **Nomura DK**, Dix MM, Cravatt BF. (2010) Chemoproteomic Approaches for Biochemical Pathway Discovery in Cancer. *Nature Reviews Cancer* 10, 630-638. PMID: 20703252
158. **Nomura DK**, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell* 140, 49-61. PMID: 20079333

159. Long JZ, **Nomura DK**, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF. (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. *Proceedings of the National Academy of Sciences, USA* 106, 20270-20275. PMID: 19918051
160. Long JZ, **Nomura DK**, Cravatt BF. (2009) Mechanistic characterization of selective monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. *Chemistry & Biology* 16, 744-753. PMID: 19635411
161. Ruby M\*, **Nomura DK\***, Hudak CS, Mangravite LM, Chiu S, Casida JE, Krauss RM. (2008) Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. *Proceedings of the National Academy of Sciences, USA* 105, 14561-14566. PMID: 18794527 (\* co-first author)
162. **Nomura DK**, Ward AM, Hudak CS, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL, Lichtman A, Casida JE. (2008) Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. *Bioorganic Medicinal Chemistry Letters* 18, 5875-5878. PMID: 18752948
163. Casida JE, **Nomura DK**, Vose SC, Fujioka K. (2008) Organophosphate-Sensitive Lipases Modulate Brain Lysophospholipids, Ether Lipids and Endocannabinoids. *Chemico-Biological Interactions* 175, 355-64. PMID: 18495101
164. **Nomura DK**, Blankman JL, Simon GM, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida JE. (2008) Activation of the endocannabinoid system by organophosphorus nerve agents. *Nature Chemical Biology* 4, 373-378. PMID: 18438404
165. **Nomura DK**, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida JE. (2008) Dual Roles of Brain Serine Hydrolase KIAA1363 in Ether Lipid Metabolism and Organophosphate Detoxification. *Toxicology and Applied Pharmacology* 228, 42-482. PMID: 18154358
166. **Nomura DK**, Durkin KA, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2006) Serine Hydrolase KIAA1363: Toxicological and Structural Features with Emphasis on Organophosphate Interactions. *Chemical Research in Toxicology* 19, 1142-1150. PMID: 16978018
167. Quistad GB, Liang SN, Fisher KJ, **Nomura DK**, Casida JE. (2006) Each Lipase has a Unique Sensitivity Profile for Organophosphorus Inhibitors. *Toxicological Sciences* 91, 166-172. PMID: 16449251
168. **Nomura DK**, Leung D, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2005) A Brain Detoxifying Enzyme for Organophosphorus Nerve Poisons. *Proceedings of the National Academy of Sciences, USA* 102, 6195-6200. PMID: 15840715
169. Segall Y, Quistad GB, Sparks SE, **Nomura DK**, Casida JE. (2003) Toxicological and Structural Features of Organophosphorus and Organosulfur Cannabinoid CB1 Receptor Ligands. *Toxicological Sciences* 76, 131-137. PMID: 12944568
170. Segall Y, Quistad GB, **Nomura DK**, Casida JE. (2003) Arachidonylsulfonyl Derivatives as Cannabinoid CB1 Receptor and Fatty Acid Amide Hydrolase Inhibitors. *Bioorganic Medicinal Chemistry Letters* 13, 3301-3303. PMID: 12951114
171. Quistad GB, **Nomura DK**, Sparks SE, Segall Y, Casida JE. (2002) Cannabinoid CB1 Receptor as a Target for Chlorpyrifos Oxon and Organophosphorus Pesticides. *Toxicology Letters* 135, 89-93. PMID: 12243867
172. Quistad GB, Sparks SE, Segall Y, **Nomura DK**, Casida JE. (2002) Selective Inhibitors of Fatty Acid Amide Hydrolase Relative to Neuropathy Target Esterase and Acetylcholinesterase: Toxicological Implications. *Toxicology and Applied Pharmacology* 179, 57-63. PMID: 11884237

## Patents

1. **Nomura DK**, Lim M, Do Cong T. DCAF16-based covalent handle for rational design of monovalent degraders. Provisional application filed on January 21st, 2024.
2. **Nomura DK**, Gowans GA, Forte N. Covalent Degradation of Oncogenic Transcription Factors. Provisional application filed on October 25th, 2023.
3. Shao Q, **Nomura DK**. Covalent Molecular Glue Stabilizers and Platform. PCT/US22/51591. PCT conversion filed on December 1st, 2022.
4. McKenna J, **Nomura DK**, Toriki E, Papatzimas J, Dovala D, Hesse M, Nishikawa K. Molecular Glue Degradation Compounds and Uses Thereof. PCT/US23/35642. PCT conversion filed October 21, 2023.



5. **Nomura DK**, Henning NJ, Spradlin JN, Ward CC, McKenna JM, Schirle M, Tallarico JA, Hesse M, Dovala D. Deubiquitinase Targeting Chimeras and Related Methods. PCT/US2022/027120; WO2022232634A1.
6. Rape M, **Nomura DK**, Henning N, Manford A. FEM1B protein binding agents and uses thereof. PCT application; PCT/US2021/021347; WO2021183431A1.
7. **Nomura DK**, Cioffi A, Schirle M, Boike L, Tallarico JA, McKenna JM, Liu G. MYC inhibitors and uses thereof. Provisional patent application filed. Abandoned
8. **Nomura DK**, Zoncu R, Chung YSC, Shin H, Canham S. mTORC1 inhibitors for Activating autophagy. PCT/US2020/013158; WO2020146779A1.
9. **Nomura DK**, Roberts AM, Bateman LA, Miyamoto DK, Huffman TR, Ward CC. Compositions and methods for modulating UBA5. PCT/US2018/016649; WO2018144869A1.
10. **Nomura DK**, Zoncu R, Roberts AM, Cho, KF, Chung YSC, Shin J, Croze B. mTORC1 modulators; Patent US20190112268A1.
11. **Nomura DK**, Zoncu R, Ward C, Fung SK, Varma CK, Fontaine B. Methods and compounds for targeted autophagy. Patent US20190290778A1.
12. Spradlin J, Ward CC, **Nomura DK**, Schirle M, Tallarico JA, McKenna JM, Maimone TJ, Hu X. Covalent targeting of E3 ligases. Patent US20210369731A1.
13. **Nomura DK**, Anderson KE. Thioredoxin modulators and uses thereof. PCT/US2018/024134; WO2018175958A1.
14. **Nomura DK**, Roberts LS, Ward CC. Compositions for treating breast cancer. PCT/US2018/017702; WO2018148598A1.
15. **Nomura DK**, Grossman EA, Ward CC, Bateman LA, Huffman TR, Miyamoto DK, Spradlin JL. Compositions and methods for modulating ppp2r1a. Patent US20200054651A1.
16. **Nomura DK**, Olzmann JA, Bateman LA, Nguyen TB, Miyamoto DK, Huffman TR, Roberts AM. Compositions and methods for inhibiting Reticulon 4. Patent US20200062696A1.
17. Bachovchin D, Chang JW, Cravatt BF, Li W, Moellering RE, **Nomura DK**. Anti-cancer serine hydrolase inhibitory carbamates. Patent US9249128B2.
18. Cravatt BF, Long JZ, Li W, **Nomura DK**. Methods and Compositions Related to Targeting Monoacylglycerol Lipase. Patent US8772318B2.

### Abstracts/meetings/invited talks

1. Hamilton Lecture Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Temple University, Philadelphia, Pennsylvania.
2. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. National Cancer Institute seminar series, Maryland.
3. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Society for Laboratory Automation and Screening meeting, Boston, Massachusetts.
4. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Targeted Protein Degradation and Induced Proximity Keystone meeting, Keystone, Colorado.
5. Invited speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Beth Israel Deaconess Medical Center Cancer Research Institute seminar series, Boston, Massachusetts.
6. Plenary Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 13th International Symposium on Bioorganic Chemistry, Singapore.
7. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Ubiquitin Biology and Disease Keystone Meeting, Keystone, Colorado.
8. Keynote Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Chemistry at the Interface of Biology and Medicine Symposium, Columbia University, New York, New York.
9. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts.
10. Keynote Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 45th Princeton ACS Fall Organic Chemistry Symposium, Princeton, New Jersey.

11. Keynote Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 Purdue University Drug Discovery symposium, West Lafayette, Indiana.
12. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Leiden University Department of Chemistry, Leiden, Netherlands.
13. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Technical University of Munich Department of Chemistry, Munich, Germany.
14. Invited Speaker: **Nomura DK** (2023) Using Covalency to Enable Drug Discovery. Novartis Institutes for BioMedical Research, Basel, Switzerland.
15. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 Induced Proximity Drug Discovery Summit, Boston, Massachusetts.
16. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 Activity-Based Protein Profiling Meeting, Tel Aviv, Israel.
17. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Boston University's Center for Molecular Discovery 2023 Symposium, Boston, MA.
18. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Proximity-inducing pharmacology: Targeted protein degradation and beyond meeting, IRB Barcelona, Barcelona, Spain.
19. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Massachusetts General Hospital Cancer Center Seminar Series, Boston, MA.
20. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Special Seminar at Pfizer, Groton, CT.
21. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 5th Annual Symposium on Applied Synthesis, Connecticut College, CT.
22. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Novalix Conference on Biophysics in Drug Discovery, Philadelphia, Pennsylvania.
23. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. University of Florida Scripps Symposium, Jupiter, Florida.
24. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. AACR meeting in Orlando, Florida.
25. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Cambridge Healthtech Drug Discovery Chemistry conference, San Diego, CA
26. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Cambridge Healthtech Drug Discovery Chemistry conference, San Diego, CA
27. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Yale University, Department of Molecular, Cellular, and Developmental Biology Seminar Series, New Haven, CT.
28. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Third Rock Ventures Covalent Drug Discovery Symposium, Boston, MA
29. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Center, Targeted Protein Degradation Seminar Series, Boston, MA.
30. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Kisaco Targeted Degradation and Undruggables Summit, Boston, MA.
31. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Baylor College of Medicine, Houston, TX.
32. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Japan Chemical Biology meeting, Osaka, Japan.
33. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Princeton University Department of Chemistry seminar series, Princeton, NJ.
34. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Hanson Wade Molecular Glue Degradation Summit, Boston, MA.
35. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Harvard Medical School Department of Cell Biology student invite, Boston, MA.
36. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Illinois, Urbana Champagne, 18th Annual CBI TP Symposium for the Chemistry-Biology Interface Training Program (CBITP), Urbana-Champagne, Illinois.

37. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. FASEB Ubiquitin and Ubiquitin-like proteins conference, Boston, MA.
38. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Applied Pharmaceutical Chemistry Symposium, Cambridge, MA.
39. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. 2<sup>nd</sup> Metabolism in Health and Disease, Cancun, Mexico.
40. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. 2<sup>nd</sup> Induced Proximity-Based Drug Discovery Summit, Boston, MA.
41. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. American Association of Cancer Research meeting, New Orleans, LA.
42. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. UC Santa Cruz Department of Chemistry seminar series, Santa Cruz, CA.
43. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. RSC Fragment based drug discovery, Cambridge, UK.
44. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Pennsylvania, Department of Chemistry, Virtual.
45. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity Targeting and Undruggables Conference, Boston, MA.
46. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Johns Hopkins University, Chemical Biology Interface Program student invite, Baltimore, Maryland.
47. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Pacific Chem Conference, Virtual.
48. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. NYAS Targeted Protein Degradation: From Drug Discovery to the Clinic, Virtual
49. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at Emory University, Atlanta, GA.
50. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Southern California, Los Angeles, CA.
51. Keynote Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. International Chemical Biology Society meeting, Virtual
52. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. LMU Munich Organic Chemistry seminar, Virtual
53. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at UC Irvine, Irvine, CA.
54. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Minnesota, Minneapolis, Minnesota.
55. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Discovery on Target meeting, Cambridge, MA
56. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Novartis: Frontiers of Science and Medicine Institutional Lecture, Cambridge, MA
57. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Institute Chemical Biology Symposium, Virtual
58. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. European Targeted Protein Degradation meeting, Virtual
59. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Vertex research seminar, Boston, MA
60. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity-Based Drug Discovery Summit, Hanson Wade, Virtual.
61. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. BioTechne Symposium: Advances in Targeted Protein Degradation, Virtual
62. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Ligase Targeting Drug Development, Hanson Wade, Virtual.
63. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. AACR meeting Chemistry in Cancer Research Town Hall, Virtual
64. Invited Speaker: **Nomura DK** (2021) Developing Coronavirus Anti-Viral Drugs. Center for Emerging and Neglected Diseases Symposium, Virtual.

65. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Helmholtz Drug Discovery Conference Speaker, Virtual.
66. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Rutgers University seminar speaker, Virtual.
67. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. North American Protein Degradation Congress meeting, Kisaco Research, Virtual.
68. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Targeted Protein Degradation & PROTAC symposium, Oxford Global, Virtual.
69. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Stanford University, Department of Chemistry, Virtual.
70. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. SLAS International Conference, Virtual.
71. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. UCSF Cancer Center, Virtual.
72. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Center Targeted Protein Degradation Seminar Series, Virtual.
73. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Janssen, Virtual.
74. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Oregon Health Sciences University, Virtual.
75. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. 3<sup>rd</sup> Annual Targeted Protein Degradation Meeting, Virtual.
76. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. 18<sup>th</sup> Annual Discovery on Target Conference, Virtual.
77. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University Department of Chemistry, Virtual.
78. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Pfizer, Virtual.
79. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Transcription Factor Drug Development Conference, Virtual.
80. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Cygnal Therapeutics, Virtual.
81. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Natural Products Symposium at the New York Academy of Sciences, Virtual.
82. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. North American Targeted Degradation Summit. San Diego, CA.
83. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. The Mark Foundation for Cancer Research Induced Proximity Meeting, New York, New York
84. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. MIT/Broad Institute Chemical Biology seminar series, Cambridge, MA
85. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Calico, South San Francisco, CA
86. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. California Institute of Technology Chemical Biology seminar series, Pasadena, CA
87. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. UT San Antonio, San Antonio, TX.
88. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Harvard University Chemistry and Chemical Biology seminar speaker, Cambridge, MA
89. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Memorial Sloan Kettering Cancer Center, New York, NY.
90. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Bayer Life Science Workshop: Chemical Biology—Jointly Exploring New Frontiers, Berlin, Germany
91. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. 2<sup>nd</sup> Targeted Protein Degradation Summit meeting, Boston, MA
92. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University, Chicago, IL.

93. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. American Chemical Society meeting, Targeted Protein Degradation session, San Diego, CA.
94. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Janssen Pharmaceuticals seminar speaker, Springhouse, Pennsylvania.
95. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Targeted Drug Discovery Summit, Boston, MA.
96. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. 60<sup>th</sup> International Conference on the Biosciences of Lipids, Tokyo, Japan.
97. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Bioorganic Chemistry Gordon Research Conference, Andover, NH.
98. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Novartis Institutes for BioMedical Research, Basel, Switzerland.
99. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. European Targeted Protein Degradation meeting, Basel, Switzerland
100. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Cayman Chemical Biology Symposium at the University of Michigan, Ann Arbor, Ann Arbor, MI.
101. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Yale Chemical Biology symposium, New Haven, CT.
102. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. World Molecular Engineering Network meeting, Cabo San Lucas, Mexico.
103. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. American Cancer Society meeting, Orlando, FL.
104. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Structural Genomics Consortium Targeted Protein Degradation meeting, Toronto, CA.
105. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Mark Foundation for Cancer Research Symposium, New York, NY.
106. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Medicinal and Bioorganic Chemistry Foundation meeting, Steamboat, CO.
107. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. 1<sup>st</sup> Targeted Protein Degradation Summit meeting, Boston, MA
108. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Merck and Co. Organic Chemistry Seminar Series, Kenilworth, NJ.
109. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Caltech Department of Chemistry, Pasadena, California.
110. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. EMBO Enzymes and Catalysis meeting, Pavia, Italy.
111. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. City of Hope Research Institute, Los Angeles, CA
112. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Structural Genomics Consortium on Target 2035. Berlin, Germany
113. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. BASF Metanomics, Berlin, Germany
114. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Pharmaron, Beijing, China.
115. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. BASF-CARA Symposium, Santa Barbara, CA.
116. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Cambridge Healthtech Institute's 17<sup>th</sup> Annual World Preclinical Congress, Boston, MA.
117. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. ACS National Medicinal Chemistry Symposium, Nashville, TN.
118. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Merck, South San Francisco, CA.
119. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. 2018 San Antonio Drug Discovery Symposium, San Antonio, TX.
120. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. AACR meeting, Chicago, IL.

121. Invited Speaker and Session Chair: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. ASBMB meeting, San Diego, CA.
122. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Agios, Cambridge, MA.
123. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Astrazeneca, Waltham, MA.
124. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. University of California, Riverside, Riverside, CA.
125. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Tumor Metabolism Keystone meeting, Snowbird, Utah.
126. Invited Speaker: **Nomura DK** (2017) Redefining Toxicology and Druggability using Chemoproteomic Platforms. Superfund Research Program meeting, Philadelphia, Pennsylvania.
127. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. Tufts University Medical School, Boston, MA.
128. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. University of Virginia, Charlottesville, VA.
129. Invited Speaker and Wendell Griffith Lecturer: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. St Louis University, St. Louis, MO.
130. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. AACR Advances in Breast Cancer Meeting, Hollywood, CA.
131. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. Austrian Proteomics Association meeting, Graz, Austria.
132. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. Enzymes, Coenzymes, & Metabolic Pathways Gordon Conference. Waterville Valley, NH.
133. Invited Speaker: **Nomura DK** (2017) Chemoproteomic and Metabolomic Platforms for Mapping Drivers of Disease. American Diabetes Association meeting. San Diego, CA.
134. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. Royal Society of Chemistry Chemical Biology Symposium. London, UK.
135. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. World Molecular Engineering Network conference, San Jose Del Cabo, Mexico.
136. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, UCSF Breast Oncology Program Seminar, San Francisco, CA.
137. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, Cold Spring Harbor Laboratory, Chemistry and Metabolism Symposium, Cold Spring Harbor, NY.
138. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, Johns Hopkins Medical School, Department of Biological Chemistry, Baltimore, Maryland.
139. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, The University of Sydney Charles Perkin Centre, Sydney, Australia.
140. Keynote Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Third Australian Lipids Meeting, Melbourne, Australia.
141. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, University of Georgia, Athens, Georgia.
142. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, UCSD Metabolomics Symposium, La Jolla, CA.
143. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Oregon Health State University, Portland, Oregon.
144. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Amgen South San Francisco, CA
145. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Vanderbilt University Chemical Biology Seminar Series, Nashville, Tennessee.
146. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Toxicology and Drug Discovery GETA (Genetic and Environmental Toxicology Association) Symposium, Oakland, CA.
147. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Gilead Medicinal Chemistry Seminar Series, Foster City, CA.



148. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Gordon Conference on Bioorganic Chemistry, New Hampshire.
149. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. AACR National Meeting, New Orleans, Louisiana.
150. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. University of Pavia, Italy.
151. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Medical University of Graz, Graz, Austria.
152. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Keystone Science Lecture Speaker at National Institutes for Environmental Health Sciences, Research Triangle Park, North Carolina.
153. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Cleveland Clinic, Cleveland, Ohio.
154. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Purdue University, Department of Nutrition, Indiana.
155. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCLA, Los Angeles, California.
156. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. University of Wisconsin, Madison Department of Biochemistry, Madison, Wisconsin.
157. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSF Cancer Center, San Francisco, CA
158. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSF Endocrinology, San Francisco, CA
159. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSD Bioengineering Department, La Jolla, CA
160. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Dana Farber Cancer Institute, Boston, Massachusetts.
161. Invited Keynote Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Molecular and Cell Biology of Lipids Gordon Conference, Waterville Valley, New Hampshire.
162. Poster Presenter: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. High Throughput Chemistry and Chemical Biology Gordon Conference, New London, New Hampshire.
163. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. AACR Metabolism and Cancer meeting, Bellevue, Washington.
164. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Lipid Maps Meeting 2015, La Jolla, CA.
165. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, Dana Farber/Harvard Medical School, Boston, MA.
166. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, Searle Meeting, Chicago, IL.
167. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, University of Chicago, Chicago, IL.
168. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Lipid Metabolism in Disease using Chemoproteomic and Metabolomic Platforms, RIKEN, Yokohama, Japan.
169. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Lipid Metabolism in Disease using Chemoproteomic and Metabolomic Platforms, Phospholipase Meeting, Tokyo, Japan.
170. Seminar speaker: **Nomura DK** (2014) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology, UC Berkeley, Nutritional Sciences and Toxicology Department
171. Poster/Talk: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Gordon Conference, Coenzymes, and Metabolic Pathways, Waterville Valley, NH.
172. Invited Speaker: **Nomura DK** (2014) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology, Genentech, South San Francisco, CA Investigative Toxicology Division

173. Poster: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Searle Scholars Meeting, Chicago, IL.
174. Invited Speaker: **Nomura DK** (2014) Mapping Dysregulated Lipid Metabolism in Cancer using Chemoproteomic and Metabolomic Platforms, ASBMB meeting, San Diego, CA.
175. Invited Speaker: **Nomura DK** (2014) Mapping Dysregulated Lipid Metabolism in Cancer using Chemoproteomic and Metabolomic Platforms, Keystone Meeting on Tumor Metabolism, Whistler, Canada.
176. Invited Speaker: **Nomura DK** (2014) Validating Monoacylglycerol Lipase Inhibitors in Combatting Parkinson's Disease, Michael J Fox Foundation, New York, NY.
177. Invited Seminar Speaker: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, Karolinska Institute, Stockholm, Sweden.
178. Invited Seminar Speaker: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, University of Pavia, Pavia, Italy.
179. Invited Seminar Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, Novartis, Cambridge, MA.
180. Invited Seminar Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, UC Merced, Merced, CA.
181. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates eicosanoids that promote inflammation. Bioactive Lipids in Cancer, Inflammation, and Related Diseases meeting, San Juan, Puerto Rico—received Eicosanoids Research Foundation Young Investigator Award.
182. Keynote Speaker: **Nomura DK** (2013) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology. NorCal Society of Toxicology meeting, South San Francisco, CA.
183. Invited Speaker: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Symposium on Frontier Sciences on New Drug Discovery, Tsinghua University, Beijing, China.
184. Invited Speaker: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Transatlantic Frontiers of Chemistry (TFOC) meeting, American Chemical Society, Kloster Seon, Germany.
185. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates eicosanoids that promote inflammation. Gordon conference Molecular and Cellular Biology of Lipids, New Hampshire, NJ
186. Poster: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in cancer. Gordon conference bioorganic chemistry, New Hampshire, NJ.
187. Poster: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Searle Scholars Meeting, Chicago, IL.
188. Invited Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Functional Proteomic and Metabolomic Platforms. Seminar speaker at UC Berkeley, Department of Molecular and Cell Biology, Berkeley, CA
189. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Seminar speaker at University of Minnesota, Minneapolis, MN.
190. Invited Speaker: **Nomura DK** (2012) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Seminar speaker at Agilent, Santa Clara, CA.
191. Invited Speaker: **Nomura DK** (2012) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Seminar speaker at Pfizer Neuroscience, Cambridge, MA.
192. Invited Speaker: **Nomura DK** (2012) Mapping Dysregulated Metabolic Pathways using Functional Chemoproteomic and Metabolomic Platforms. Seminar Speaker at Children's Hospital Oakland Research Institute, Oakland, CA.
193. Keynote Invited Speaker: **Nomura DK** (2012) Mapping dysregulated metabolic pathways in cancer using functional proteomic and metabolomic platforms. Austrian Proteomics Research Symposium, Graz, Austria.
194. Invited Speaker: **Nomura DK**. (2012) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *International Cannabinoid Research Society* meeting, Freiberg, Germany.
195. Poster: **Nomura DK** and Samad TA (2012) Metabolomic profiling for mapping anti-inflammatory pathways in neurodegenerative disease. *Genetics and Chemistry Cell Symposium*, Cambridge, Massachusetts.
196. Invited Speaker: **Nomura DK** (2012) Endocannabinoid hydrolysis generates brain eicosanoids that promote neuroinflammation. *SciCafe* hosted by Nature Biotechnology and Nature Medicine at the Gladstone Institute, San Francisco, CA



197. Poster: **Nomura DK** and Cravatt BF (2011) Monoacylglycerol Lipase Exerts Bidirectional Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer. Cancer Chemical Biology meeting sponsored by Nature Chemical Biology, Cambridge, Massachusetts.
198. Invited Speaker: **Nomura DK** (2011) Mapping dysregulated metabolic pathways in cancer using activity-based proteomics. American Chemical Society meeting, Denver, Colorado.
199. Invited Speaker: **Nomura DK**, Cravatt BF (2011) Mapping dysregulated metabolic pathways in cancer. American Association for Cancer Research meeting, Orlando, Florida.
200. Invited Speaker: **Nomura DK**, Long JZ, Cravatt BF, Casida JE. (2010) Annotating the role of monoacylglycerol lipase in cancer and in the brain. American Chemical Society meeting, San Francisco, California.
201. Invited Speaker: **Nomura DK**. (2009) Chemical Approaches to Annotating Toxicological and Biological Systems. University of California Toxic Substances & Teaching Program Symposium, Berkeley, California.
202. Poster: **Nomura DK**, Blankman JL, Simon GM, Cravatt BF, Casida JE. (2008) Maximal activation of the endocannabinoid system by organophosphorus nerve agents. University of California Toxic Substances Research & Teaching Program Symposium, Riverside, California.
203. Poster: **Nomura DK**, Casida JE. (2007) Acetyl monoalkylglycerol ether deacetylase: an organophosphate detoxifying enzyme and modulator of tumor growth. IXth Meeting on Cholinesterases, Souzhou, China.
204. Oral Presentation: **Nomura DK**, Durkin KA, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2006) Toxicological and Structural Features of KIAA1363: A Novel Detoxifying Enzyme for Organophosphorus Nerve Poisons. American Chemical Society meeting, San Francisco, CA.
205. Poster: **Nomura DK**, Leung D, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2005) A Brain Detoxifying Enzyme for Organophosphorus Nerve Poisons. American Chemical Society meeting, Washington, D.C.

#### Students/Researchers Supervised (w/ former and current position)

Name	Position in the lab	Current Position
Christine Vo (2023-current)	Undergraduate Researcher	
Anna Chen (2023-current)	Undergraduate Researcher	
Jon Giller (2023-current)	Undergraduate Researcher	
Elijah Lee (2023-current)	Undergraduate Researcher	
Claire Song (2023-current)	Undergraduate Researcher	
Amy Tsao (2023-current)	Undergraduate Researcher	
Christian Stieger (2024-current)	Postdoctoral Fellow	
Kohei Toh (2023-2024)	Postdoctoral Fellow	
Carolyn Glasser (2023-current)	Graduate Student	
Pooreum (Christina) Seo (2023-current)	Graduate Student	
Alicia (Flor) Gowans (2023-current)	Postdoctoral Fellow	
Zoe Duong (2023-current)	Graduate Student	
Inji Park (2023-current)	Undergraduate Researcher	
Alicia Zhang (2023-current)	Undergraduate Researcher	
Tasha Tanabe (2023-current)	Undergraduate Researcher	
Kohei Toh (2023-current)	Postdoctoral Fellow	
Erica Quitales (2023-current)	Postdoctoral Fellow	
Thang Docong (2023-current)	Postdoctoral Fellow	
Brynne Currier (2023-current)	Undergraduate Researcher	
Aman Modi (2022-current)	Graduate Student	
Justin Hatcher (2022-current)	Undergraduate Researcher	
Taylor Nuttall (2022-current)	Graduate Student	
Lily Garelick (2022-current)	Undergraduate Researcher	
Yuki Terauchi (2022-2023)	Visiting Scholar	Scientist at Otsuka Pharma
Melissa Lim (2022-current)	Graduate Student	
Hannah Rosen (2022-current)	Graduate Student	
Seong Ho (Johnny) Hong (2022-2023)	Postdoctoral Fellow	Scientist at Stealth startup



Katherine Near (2017-2019) Alexander Cioffi (2017-2019) Lisha Ou (2017-2019) Linda Waldherr (2017-2017) Raymond Ho (2017-2018)	Postdoctoral Fellow Postdoctoral Fellow Undergraduate Researcher Visiting Grad Student Undergraduate Researcher	Assistant Professor at Hong Kong University Scientist at Nurix Scientist at Frontier Medicines PhD program at Stanford University Postdoc, Medical Univ of Graz Research Assistant at University of Utah
Sage Geher (2017-2017) Mai Luo (2016-2020)	Undergraduate Researcher Postdoctoral Fellow	
Tamara Tomin (2016-2017)	Visiting Grad Student	Assistant Professor at China Agricultural University Senior Scientist at Technische Universitat Wien
Alex Renn (2016-2017) Jordan Kleinman (2016-2019) Ashley Ives (2016-2017)	Undergraduate Researcher Research Associate Undergraduate Researcher	PhD program at UCSF PhD program at Northwestern University
Sultana Mojadidi (2016-2016) Jessica Spradlin (2016-2020) Carl Ward (2016-2020) Allison Roberts (2015-2018) Amanda Wiggenhorn (2016-2019) Joseph Hendricks (2016-2017) Anna Flury (2016-2016) Haley Lehtola (2016-2018)	Undergraduate Researcher Graduate Researcher Graduate Researcher Graduate Researcher Research Associate Undergraduate Researcher Lab Assistant Undergraduate Researcher	Scientist at Interline Therapeutics F99/K00 Postdoc at UCSF Senior Scientist at Frontier Medicines PhD program at Stanford University PhD program at UC Berkeley
Yana Petri (2016-2019) Justin Wang (2016-2017) Ivan Atencio (2016-2017) Andrew Hong (2016-2016) Catherine Cascavita (2015-2016) Elizabeth Grossman (2014-2019) Michelle Luu (2015-2017) Deepika Raghavan (2015-2016) Peter Yan (2015-2017) Kimberly Anderson (2015-2018) Melanie Hubbuck (2015-2017) Megan Duckering (2015-2016)	Research Associate Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Lab Manager Graduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Graduate Researcher Graduate Researcher Undergraduate Researcher	Medical student at Western University of Health Sciences PhD program at MIT PhD program at Scripps Research Process Engineer at EXP
Angela Yang (2015-2015)		Associate at Genentech Principal Scientist at Novartis Emergency Room Scribe at Vituity Medical Student at University of Iowa Medical Student at UCLA Scientist at Frontier Medicines PhD student at Washington University Senior Life Sciences Consultant at Guidehouse
Charles Berdan (2014-2019)	Undergraduate Researcher	Research Assistant at Stanford University Associate Consultant with McKinsey and Company
Wan-Min Ku (2014-2017) Derek Barbas (2014-2015) Leslie Bateman (2014-2016) Breanna Ford (2014-2019) Wallace Lowe (2014-2015) Tucker Huffman (2014-2017) Olivia Dibenedetto (2014-2014) Jeffrey Coleman (2014-2014) Lara Bideyan (2014-2015) Esha Dalvie (2013-2016) Daniel Li (2013-2015) Jessica Counihan (2013-2018)	Graduate Researcher  Undergraduate Researcher Undergraduate Researcher Postdoctoral Fellow Graduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Graduate Researcher	Senior Scientist at Neomorph Scientist at BASF
Sharon Zhong (2013-2015) David Miyamoto (2013-2015)	Undergraduate Researcher	Scientist at Ferring Pharmaceuticals Account Manager at Quantcast Scientist at NeoGenomics Labs Postdoc at UT Southwestern Postdoc at MIT Postbac at NIH Consultant for ClearView Healthcare Partners

Karl Fisher (2013-2014) Lauryn Chan (2013-2014) Lucky Ding (2013-2016) Nivedita Keshav (2013-2014) Ann Heslin (2013-2015) Chynna Tang (2013-2014)	Undergraduate Researcher Associate Specialist Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher	PhD program at Harvard University Director of Chemistry at Lygos Food Technologist at Beyond Meat Medical Student at UCSF Medical Student at UCLA Associate Product Manager at Veeva Graduate student in UC Berkeley Optometry Program Research Assistant at Genentech Senior Research Biologist at 3M Senior Scientist, Nuredis Inc. Medical Doctor
Yoav Azaria (2012-2014) Devon Hunerdosse (2012-2015) Lindsay Roberts (2012-2017) Ramandeep Dhillon (2012-2015) Alice Shieh (2012-2013) Tara Narasimhalu (2012-2014) Rebecca Kohnz (2012-2016) Patrick Morris (2012-2014) Melinda Mulvihill (2012-2014) Alyssa Cozzo (2012-2013) Daniel Medina-Cleghorn (2011-2015) Jay Andrew Cosme Barcelon (2011-2012) McKenna Green (2012-2014)	Undergraduate Researcher Graduate Researcher Graduate Researcher Administrative and Lab Asst. Undergraduate Researcher Undergraduate Researcher Postdoctoral Fellow Postdoctoral Fellow Postdoctoral Fellow Undergraduate Researcher Graduate Researcher  Undergraduate Researcher  Undergraduate Researcher	Undergraduate at Duke University Medical Resident at UCLA Senior Scientist at Merck Staff Scientist at NCI/NIH Senior Scientist at Genentech Researcher in Mina Bissell Lab, LBNL Scientist at Nurix  Strategic Market Access & Intelligence Analyst at XCenda Resident Physician at Detroit Medical Center Postdoc at Stanford in Tom Rando Lab Scientist at CohBar Graduate Student at SF State Postdoctoral Fellow at U. Chicago Anesthesiology Resident at Harvard Medical School Principal Compliance Manager at Genentech
Daniel I Benjamin (2011-2015) Sharon M Louie (2011-2017) Anayo Ohiri (2011-2013) Jae Wong Chang (2009-2011) Anna M. Ward (2004-2008, 2010)  Roger Issa (2004-2008)	Graduate Researcher Graduate Researcher Undergraduate Researcher Graduate Researcher Undergraduate Researcher  Undergraduate Researcher	

### **Current Research Support**

Oerth Bio Oerth-Berkeley Center for Targeted Protein Degradation in Agriculture	Nomura (PI)	12/1/2023-11/31/2026 \$261,000/yr direct cost (Nomura)
Lyterian Therapeutics Sponsored Research Agreement Using chemoproteomic platforms to tackle Lyterian targets	Nomura (PI)	7/1/2023-6/30/2025 \$200,000/yr direct cost (Nomura)
Octant Sponsored Research Agreement Using chemoproteomic platforms to tackle Lyterian targets	Nomura (PI)	7/15/2023-6/14/2025 \$30,000/yr direct cost (Nomura)
NIH/NCI R35CA263814 R35 Outstanding Investigator Award Tackling Undruggable Cancer Targets using Chemoproteomic Platforms Tackling undruggable cancer targets using covalent chemoproteomic strategies	Nomura (PI)	8/1/2022-7/30/2029 \$600,000/yr direct cost (Nomura)
Novartis Institutes for BioMedical Research Novartis-Berkeley Translational Chemical Biology Institute (Maimone, Toste, Olzmann, Zhang also Institute members)	Nomura (Director)	7/1/22-6/30/27 \$1,700,000/yr direct cost (Nomura)

Using chemoproteomic platforms to tackle the undruggable proteome

Amgen  
Amgen-Berkeley Chemoproteomics Center of Excellence  
Nomura (Director)  
1/1/22-12/30/24  
\$500,000/yr direct cost (Nomura)

Using chemoproteomic platforms to develop new therapeutic modalities

Apple Tree Ventures (ATP)  
Nomura (PI)  
3/1/2022-2/28/2024  
\$200,000/yr total cost (Nomura)

Discovering Covalent Molecular Glues to Therapeutically Target Undruggable Cancer Targets

NSF  
Molecular Foundations for Biotechnology Award (2127788)  
Developing Next-Generation Approaches to Targeted Protein Degradation  
Nomura (PI)  
8/1/2021-7/31/2024  
\$500,000/yr (Nomura)

Mark Foundation for Cancer Research  
ASPIRE award Phase II  
Nomura (PI)  
1/1/21-12/31/25  
\$454,454/yr direct cost (Nomura)

NIH/NCI  
R01CA240981 R01 Research Project Grant  
Harnessing E3 Ligases for Cancer Therapy  
Characterizing the role of nimbolide and RNF114 in cancer and for targeted protein degradation.  
Nomura (PI)/Maimone (PI)  
7/1/2019-6/30/2024  
\$161,999/yr direct cost (Nomura)

NIH/NIGMS  
R01GM136945 R01 Research Project Grant  
Chemical synthesis and biology of complex alkaloids  
Synthesizing and performing target identification studies on complex alkaloids  
Nomura (PI)/Maimone (PI)  
4/1/2020-3/31/2024  
\$154,000/yr direct cost (Nomura)

### **Previous Research Support**

Otsuka Pharmaceuticals  
Nomura (PI)  
1/1/2022-12/31/2023  
\$120,000/yr (Nomura)

Developing novel E3 ligase recruiters for targeted protein degradation

FASTGRANT  
Developing therapeutics against COVID-19  
Nomura (PI)  
indefinite timeline  
\$1,000,000

Gift from Sergey Brin Family Foundation  
Nomura (PI)  
indefinite timeline  
\$350,000

Daniel Nomura  
Nomura fund  
Unrestricted funds  
Nomura (PI)  
7/1/2019-indefinite  
\$100,000

Bristol Myers Squibb  
BMS-Berkeley Center for Chemical Biology and Therapeutics  
Nomura (Director)  
7/1/22-12/31/23  
\$500,000/yr direct cost (Nomura)

Using chemoproteomic platforms to tackle intractable disease targets

NIH/NCI  
Stahl A (PI)/Chen (PI)/Nomura (Sub) 8/1/18-7/31/23

R01CA221916 R01 Research Project Grant

\$26,653/yr direct cost (Nomura)/\$163,142/yr direct cost (Chen)/\$163,142/yr direct cost (Stahl)

Role of protein mediated fatty acid uptake in liver cancer

Understanding the role of fatty acid transporters to the growth of cholangiocarcinomas.

Calico  
Sponsored Research Agreement  
Using chemoproteomic platforms to develop drugs against Calico targets

Nomura (PI)

3/1/2021-2/31/2023

\$200,000/yr direct cost (Nomura)

Kymera Therapeutics  
Developing novel E3 ligase recruiters for targeted protein degradation

Nomura (PI)

4/1/22-3/31/23

\$200,000/yr direct cost (Nomura)

Novartis Institutes for BioMedical Research  
Novartis-Berkeley Center for Proteomics and Chemistry Technologies

Nomura (Director)

7/13/17-7/12/22

\$1,000,000/yr direct cost for whole center (Nomura, Toste, Chang, Maimone);

\$400,000/yr direct cost for Nomura (Nomura)

Discovering new druggable modalities to tackle the undruggable proteome

NIH/NIEHS  
R01ES028096 R01 Research Project Grant

Chang CJ (PI)/Nomura (PI)

9/1/17-8/31/22

\$111,536/yr direct cost (Nomura)

Chemical Probes for Studying Formaldehyde Biology

Developing chemical technologies for studying biological and toxicological mechanisms of formaldehyde

NIH/NIEHS  
P42ES004705 Superfund Research Program Multiproject Center Grant

Nomura (PI)/Chang (PI)

7/1/17-6/31/22

\$78,000/yr direct cost (Nomura)

Toxic Substances in the Environment Project 3

Using chemoproteomic platforms to map novel toxicological mechanisms of environmental chemicals.

Ono Pharmaceutical Co.  
Sponsored Research Agreement  
Covalent ligand discovery against Ono Pharma Targets

Nomura (PI)

12/1/19-11/31/21

\$100,000/yr direct cost

Biogen  
Sponsored Research Agreement  
Chemoproteomics-enabled covalent ligand discovery to develop new therapies against neurodegenerative diseases

Nomura (PI)

7/1/20-7/31/21

\$140,000/yr direct cost

Innovative Genomics Institute  
Innovative Genomics Institute  
Chemoproteomic Platforms to Target Cas12a  
Covalent ligand discovery against Cas12a for gene editing applications

Nomura (PI)

9/1/2019-8/31/2021

\$100,000

Frontier Medicines  
Gift  
Developing the Targeted Protein Autophagy Platform

Nomura (PI)

8/1/18-7/31/20

\$165,000/yr direct cost

Biogen  
Sponsored Research Agreement  
Chemoproteomics-enabled covalent ligand discovery to develop new therapies against neurodegenerative diseases

Nomura (PI)

8/1/18-7/31/21

\$140,000/yr direct cost

Pfizer  
1/1/18-12/31/19

Nomura (PI)

1/1/18-12/31/19

Sponsored Research Agreement Chemoproteomics-enabled covalent ligand discovery against neurological and immunological targets Discovering new targets and drugs for neurological and immunological diseases		\$250,000/yr direct cost
Mark Foundation for Cancer Research ASPIRE award Phase I/Therapeutic Innovation Award	Nomura (PI)	1/1/19-12/31/19 \$315,000/yr direct cost
Artris Therapeutics Sponsored Research Agreement Use chemoproteomic platforms to test and optimize Artris Therapeutics lead compounds	Nomura (PI)	4/1/18-3/30/19 \$80,000 direct cost
NIH/NIGMS P50GM115318 Research Centers for Pharmacogenomics Pharmacogenomics of statin response Identify, validate, and determine the function of novel markers for efficacy of statins in prevention of cardiovascular disease, and for occurrence of adverse events on statin treatment.	Krauss (PI)/Nomura (Sub)	10/1/15-5/30/19 \$70,000/yr direct cost
American Cancer Society RSG-14-242-01-TBE ACS Research Scholar Award Characterizing the Role of AGPS and Ether Lipids in Driving Cancer Determining the metabolic and pathophysiological roles of AGPS and ether lipids in breast cancer.	Nomura (PI)	1/1/15-12/31/18 \$165,000/yr direct cost
BASF BASF-CARA Target identification of BASF herbicides using chemoproteomics Using chemoproteomics to identify mechanisms of action of BASF agrochemicals	Nomura (PI)	11/1/17-10/31/18 \$60,000/yr direct cost
NIH/NCI R01CA172667 R01 Research Project Grant Annotating the Role of Dysregulated Inositol Phosphate Metabolism in Malignant Cancers Investigating the role of inositol polyphosphate phosphatase (INPP1) in driving cancer metabolism and pathogenicity	Nomura (PI)	3/1/13-2/31/18 \$250,000/yr direct cost
DOD CDMRP/BCRP CDMRP W81XWH-15-1-0050 DOD Breakthroughs Award Characterizing PAFAH1B3 as a Novel Metabolic Target for Breast Cancer Determining the metabolic and pathophysiological roles of PAFAH1B3 in breast cancer.	Nomura (PI)	7/1/15-6/30/18 \$250,000/yr direct cost
BASF BASF-CARA Award Using Chemical Systems Biology Platforms for Advancing Nutrition and Toxicology Using advanced metabolomic, proteomic, chemoproteomic, and transcriptomic platforms to understand nutrition and toxicology.	Nomura (PI)	8/1/14-7/31/17 \$150,000/yr direct cost
NIH/NIEHS P42ES004705 Superfund Research Program Multiproject Center Grant Toxic Substances in the Environment; (Core C: Proteomics and Metabolomics) Process, maintain, and store biological samples, and store cell culture lines for <i>in vitro</i> studies; provide facilities, methodologies, and bioinformatics capabilities for proteomic and metabolomics data analysis for Superfund investigators	Smith MT (PI)/Nomura (Core)	4/1/11-3/31/17 \$30,000/yr direct cost
Kinship Foundation Searle Scholars Program Mapping Dysregulated Metabolic Pathways in Cancer and Inflammatory Diseases	Nomura (PI)	7/1/12-6/30/15 \$100,000/yr direct cost

Identifying and characterizing the roles of commonly perturbed enzymatic pathways across multiple types of malignant human cancer cells; studying the role of monoacylglycerol lipase in coordinately regulating endocannabinoid and eicosanoid signaling to modulate neuroinflammation and neurodegeneration

NIH/NIDA  
K99/R00DA030908  
Nomura (PI)  
7/1/10-6/30/14  
\$159,000/yr direct cost  
Role of monoacylglycerol lipase in coordinating diverse lipid signaling pathways  
The major goals of this project are to characterize the biochemical and pathophysiological roles of monoacylglycerol lipase in cancer and neuroinflammation

NIH/NCI  
R21 CA170317  
Nomura (PI)  
8/1/12-7/31/14  
\$225,000/yr direct cost  
Remodeling of Dietary Fat into Protumorigenic Signaling Lipids in Cancer  
Determining whether cancer cells take up exogenous fat or fatty acids and remodel them into protumorigenic signaling lipids to fuel cancer malignancy

Michael J. Fox Foundation  
Target Validation Award  
Nomura (PI)  
2/1/13-1/31/15  
\$150,000/yr direct cost  
Validating Monoacylglycerol Lipase Inhibitors in Combatting Parkinson's Disease  
Testing the efficacy of monoacylglycerol lipase (MAGL) inhibitors against preclinical models of Parkinson's disease for developing MAGL inhibitors for clinical development.

Matthew Winkler gift  
Nomura (PI)  
7/1/12-6/31/13  
\$50,000 direct cost

Hellman Foundation  
Nomura (PI)  
Indefinite  
\$50,000 direct cost